WO2023089575A1 - An orodispersible pharmaceutical dosage form of edoxaban - Google Patents
An orodispersible pharmaceutical dosage form of edoxaban Download PDFInfo
- Publication number
- WO2023089575A1 WO2023089575A1 PCT/IB2022/061193 IB2022061193W WO2023089575A1 WO 2023089575 A1 WO2023089575 A1 WO 2023089575A1 IB 2022061193 W IB2022061193 W IB 2022061193W WO 2023089575 A1 WO2023089575 A1 WO 2023089575A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- edoxaban
- dosage form
- pharmaceutically acceptable
- hydrate
- acceptable salt
- Prior art date
Links
- 229960000622 edoxaban Drugs 0.000 title claims abstract description 807
- 239000002552 dosage form Substances 0.000 title claims abstract description 508
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 120
- 230000008569 process Effects 0.000 claims abstract description 117
- PSMMNJNZVZZNOI-SJILXJHISA-N edoxaban tosylate hydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 PSMMNJNZVZZNOI-SJILXJHISA-N 0.000 claims description 826
- 150000003839 salts Chemical class 0.000 claims description 358
- 239000007884 disintegrant Substances 0.000 claims description 257
- 239000000203 mixture Substances 0.000 claims description 225
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 213
- 229920000642 polymer Polymers 0.000 claims description 188
- 239000011230 binding agent Substances 0.000 claims description 151
- 239000012458 free base Substances 0.000 claims description 113
- 238000007907 direct compression Methods 0.000 claims description 105
- 150000007524 organic acids Chemical class 0.000 claims description 64
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 57
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 56
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 56
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 56
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 54
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 54
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 54
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 51
- 239000001856 Ethyl cellulose Substances 0.000 claims description 51
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 51
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 51
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 51
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 51
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 51
- 229920001249 ethyl cellulose Polymers 0.000 claims description 51
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 51
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 51
- 229920000609 methyl cellulose Polymers 0.000 claims description 51
- 235000010981 methylcellulose Nutrition 0.000 claims description 51
- 239000001923 methylcellulose Substances 0.000 claims description 51
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 51
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 51
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 38
- ZLFZITWZOYXXAW-QXXZOGQOSA-N edoxaban tosylate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 ZLFZITWZOYXXAW-QXXZOGQOSA-N 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 239000000314 lubricant Substances 0.000 claims description 13
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 12
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 12
- 206010047249 Venous thrombosis Diseases 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 11
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 11
- 239000011975 tartaric acid Substances 0.000 claims description 11
- 235000002906 tartaric acid Nutrition 0.000 claims description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- 206010014522 Embolism venous Diseases 0.000 claims description 8
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 229950008138 carmellose Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 208000004043 venous thromboembolism Diseases 0.000 claims description 8
- 239000001530 fumaric acid Substances 0.000 claims description 7
- 235000011087 fumaric acid Nutrition 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 6
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 6
- 235000015165 citric acid Nutrition 0.000 claims description 6
- 229960004106 citric acid Drugs 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 208000005189 Embolism Diseases 0.000 claims description 4
- 206010020100 Hip fracture Diseases 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 229960004365 benzoic acid Drugs 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229960005069 calcium Drugs 0.000 claims description 4
- 239000000378 calcium silicate Substances 0.000 claims description 4
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 4
- 229960003340 calcium silicate Drugs 0.000 claims description 4
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 238000013150 knee replacement Methods 0.000 claims description 4
- 238000002356 laser light scattering Methods 0.000 claims description 4
- 210000003141 lower extremity Anatomy 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 230000000399 orthopedic effect Effects 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 229960001367 tartaric acid Drugs 0.000 claims description 4
- 238000011541 total hip replacement Methods 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 3
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 claims description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- 229960000250 adipic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 229940097043 glucuronic acid Drugs 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229960005378 edoxaban tosylate Drugs 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 29
- 239000003146 anticoagulant agent Substances 0.000 abstract description 3
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 120
- 238000009472 formulation Methods 0.000 description 67
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 54
- 239000001768 carboxy methyl cellulose Substances 0.000 description 41
- 238000004090 dissolution Methods 0.000 description 30
- 239000008187 granular material Substances 0.000 description 26
- 239000007941 film coated tablet Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 239000012535 impurity Substances 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 239000006191 orally-disintegrating tablet Substances 0.000 description 9
- 238000005550 wet granulation Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000011978 dissolution method Methods 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000012495 forced degradation study Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 229940011622 savaysa Drugs 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 244000018633 Prunus armeniaca Species 0.000 description 3
- 235000009827 Prunus armeniaca Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIKVHUDEOYKYGJ-GMXVVIOVSA-N 2-[[(1s,2r,4s)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]amino]-2-oxoacetic acid Chemical compound C1[C@@H](C(=O)N(C)C)CC[C@H](NC(=O)C(O)=O)[C@@H]1NC(=O)C(S1)=NC2=C1CN(C)CC2 CIKVHUDEOYKYGJ-GMXVVIOVSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- -1 glidants Substances 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004704 glottis Anatomy 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 239000000879 neohesperidine DC Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002491 polymer binding agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention relates to an orodispersible pharmaceutical dosage form of edoxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.
- Edoxaban is represented by the structural formula (I) and its chemical name is (N'-(5-chloropyridin-2-yl)-N-[(lS,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl- 6,7-dihydro-4H-[l,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl] oxamide).
- edoxaban (Lixiana®) was approved by the European Medicines Agency (EMA) in June 2015, whereas in the US, the Food and Drug Administration (FDA) approved edoxaban (Savaysa®) in January 2015.
- EMA European Medicines Agency
- FDA Food and Drug Administration
- Edoxaban is indicated both in EU and the US in: (i) prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age > 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA), and (ii) treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults.
- NVAF nonvalvular atrial fibrillation
- TIA prior stroke or transient ischaemic attack
- VT deep vein thrombosis
- PE pulmonary embolism
- Lixiana®/Savaysa® is commercially available both in Europe and the US as immediate release film- coated tablets in 15, 30 and 60 mg strengths (based on edoxaban free base).
- the used pharmaceutically acceptable salt of edoxaban in Lixiana® /Savaysa® is e
- Edoxaban immediate-release film-coated tablets are the only available commercial dosage form in Europe (Lixiana®) and in the US (Savaysa®). These conventional tablets need to be swallowed - meaning that patients in therapy should be able to perform the action of swallowing correctly. However, swallowing may prove difficult for some category of patients, for example, for elderly patients or pediatric patients, or for patients who barely cooperate with medical personnel because of progression of disabling diseases. In these clinical situations the patient has difficulty in swallowing, and therefore it would be advisable to replace the tablets that are to be swallowed with water with other oral dosages forms in which swallowing is made easier.
- a particular solid pharmaceutical dosage form that rapidly disintegrates are orodispersible tablets (also named orally disintegrated tablet (ODT) or fast disintegrating tablets), which do not require water, and hence can be consumed in situations where patients require an easy-to-administer dosage form.
- Orodispersible tablets are an improved dosage form with respect to conventional tablets, as they are not required to be swallowed and are in line with the current fast-paced modern lifestyle.
- orodispersible tablets are especially suitable for patients suffering from dysphagia, wherein closure of the glottis and simultaneous contraction of the muscles of the larynx do not propel adequately the conventional tablet that needs to be swallowed.
- orodispersible pharmaceutical compositions comprising edoxaban.
- these suffer from the serious drawbacks of being manufactured by wet-granulation processes which require several processing steps and long manufacturing times, thus making the overall process lengthy and with high cost.
- orodispersible edoxaban compositions known from the prior art made by wet-granulation techniques tend to deliver finished drug formulations with variability with respect to the dissolution rate of edoxaban.
- Another limitation of the known orodispersible edoxaban compositions is their stability, as during wet-granulation steps edoxaban is subjected to humidity conditions (water or other solvents) or to high temperatures required for drying obtained edoxaban granules. Such harsh conditions result in stability problems of the manufactured orodispersible edoxaban compositions.
- EP3549585 discloses orally disintegrating tablets comprising edoxaban, an organic acid, 0.1 to 2.0% w/w of a water-soluble polymer relative to the total weight of the disintegrating tablet, and a disintegrant.
- edoxaban-containing granules (referred to as “drug-containing granules”) were obtained by wet-granulating a mixture comprising the active ingredient with other excipients, employing as a granulating agent an aqueous solution containing 0.1 to 2.0% w/w of a water-soluble polymer, whereas a second step consisted of wet-granulating pharmaceutically acceptable excipients, which yielded a second type of granules (referred to as “rapidly disintegrating granules ’).
- the final step consisted of mixing of both edoxaban-containmg type granules and rapidly disintegrating granules with further excipients, and compression to obtain orally disintegrated tablets.
- EP3815686 discloses edoxaban granular preparations which are manufactured by two separated and independent granulation processes which yield two different types of granules. Specifically, a first type of granules, which are edoxaban- containing granules (referred to as “drug-containing granules”) are obtained by wet-granulating a mixture of edoxaban with other excipients.
- a second type of granules are obtained by wet-granulating a mixture of xylitol or sorbitol with carmellose sodium, employing as a granulating agent either an aqueous solution containing carmellose sodium or water alone.
- edoxaban (Lixiana®) was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on April 2011. Edoxaban is approved in Japan for the same mentioned indications as for Europe and US. Additionally, it is approved in Japan for the prevention of venous thromboembolism (VTE) in patients undergoing any of the following orthopedic surgeries for the lower limbs: total knee replacement, total hip replacement, and hip fracture surgery.
- VTE venous thromboembolism
- edoxaban (Lixiana®) is also marketed as orally disintegrated tablets in 15, 30 and 60 mg strengths (based on edoxaban free base). ODT’s are distinguished from conventional sublingual tablets, buccal tablets and lozenges by their fast disintegration time in the oral cavity, which generally takes around 60 seconds or less.
- CDER Center for Drug Evaluation and Research
- BCS Biopharmaceuticals Classification System
- the inventors of the present invention have been capable of designing new orodispersible pharmaceutical dosage forms comprising edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- orodispersible pharmaceutical dosage forms of the invention obtained by direct compression, comprising edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, also have overall improved technical characteristics as summarised hereinafter.
- the dosage forms of the invention disintegrate in the tune range of from two minutes and 5 seconds, preferably in the time range of from one minute and 40 seconds and 10 seconds, more preferably in the time range of from one minute and 30 seconds and 15 seconds, and even more preferably in the time range of from one minute and 15 seconds and 20 seconds.
- This disintegration time represents an improvement with respect to 60 mg strength commercially available Lixiana® orally disintegrated tablets, which take longer than one minute and a half to completely disintegrate and which are manufactured by compressing two different types of granules (“edoxaban- containing granules” and “rapidly disintegrating granules”) obtained after two distinct and separated wet-granulation processes.
- edoxaban- containing granules and “rapidly disintegrating granules”
- edoxaban orodispersible dosage forms of the invention are suitable dosage forms for replacing conventional Lixiana® film-coated tablets in the treatment of: (i) prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, and/or (ii) treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and/or (iii) prevention of venous thromboembolism (VTE) in patients undergoing any of the following orthopedic surgeries for the lower limbs: total knee replacement, total hip replacement, and hip fracture surgery.
- NVAF nonvalvular atrial fibrillation
- VVT deep vein thrombosis
- PE pulmonary embolism
- VTE venous thromboembolism
- Edoxaban orodispersible pharmaceutical dosage forms of the invention have adequate hardness and low friability, which are important advantages in order to withstand physical shocks along manufacturing process and for storage and handling transportation. Moreover, edoxaban orodispersible pharmaceutical dosage forms of the invention have an improved stability with respect to commercially available Lixiana® orally disintegrated tablets and Lixiana® film- coated tablets.
- a disintegrant, and one or more further pharmaceutically acceptable excipients formation of degradation products can surprisingly be prevented over time.
- edoxaban orodispersible compositions of the invention comply with the strict criteria of impurities limit specifications required by the European or Japanese regulatory agencies.
- edoxaban orodispersible pharmaceutical dosage forms of the invention allow to provide reliable and adequate dissolution profile of edoxaban, thus releasing edoxaban in a sufficiently equivalent manner for being bioequivalent to immediate-release film-coated tablets of Lixiana®.
- edoxaban orodispersible dosage forms of the invention avoids the risk of being either suprabioequivalent or infrabioequivalent, which may affect the toxicity and/or the efficacy of said orodispersible dosage form. Therefore, orodispersible pharmaceutical dosage forms of the invention constitute a valuable therapeutic tool in the field of anticoagulant medicinal products.
- the inventors have also unexpectedly found that the preferable presence of two different pharmaceutically acceptable disintegrants in the orodispersible pharmaceutical dosage form of the invention provides a synergistic effect in terms of disintegration time, as well as in terms of hardness and friability.
- the interaction of two different pharmaceutically acceptable disintegrants in the orodispersible tablets of the invention achieves an improved disintegration time, hardness, friability and stability while providing an adequate dissolution profile of edoxaban.
- a first aspect of the present invention relates to an orodispersible pharmaceutical dosage form comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- a second aspect of the invention relates to a direct compression process for the preparation of the orodispersible dosage form of the first aspect of the invention, which comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form.
- a third aspect of the invention relates to the orodispersible dosage form of the fist aspect of the invention for use in: a) prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age > 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA); and/or b) treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults; and/or c) prevention of venous thromboembolism (VTE) in patients undergoing any of the following orthopedic surgeries for the lower limbs: total knee replacement, total hip replacement, and hip fracture surgery.
- NVAF nonvalvular atrial fibrillation
- TIA prior stroke or transient ischaemic attack
- Figure 1 shows the dissolution profiles of: (i) film-coated tablet of Lixiana® (60 mg strength), (ii) a Japanese commercially available orally disintegrating tablet Lixiana® (60 mg strength), (iii) Comparative Formulation 1, (iv) Formulations 2, 3 and 4.
- active ingredient refers to a pharmaceutically active molecule (e.g. edoxaban) as well as its pharmaceutically acceptable and therapeutically active salts, hydrates, esters, amides, prodrugs, metabolites, enantiomers, polymorphs, analogs, etc. that induce a desired pharmacological or physiological effect.
- a pharmaceutically active molecule e.g. edoxaban
- active pharmaceutical ingredient active substance
- drug substance drug
- edoxaban corresponds to the International Nonproprietary Name (INN) for (N'-(5-chloropyridin-2-yl)-N-[(lS,2R,4S)-4- (dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[l,3]thiazolo[5,4-c]pyridine- 2-carbonyl)amino]cyclohexyl]oxamide) but also as their pharmaceutically acceptable salts and/or hydrates.
- Pharmaceutically acceptable salts of edoxaban and their hydrates comprise any of a broad range of inorganic and organic acids.
- salts include acid addition salts with a mineral acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, or phosphoric acid, and those with an organic acid such as p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, citric acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, tartaric acid, maleic acid, malic acid, fumaric acid, mandelic acid.
- a mineral acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, or phosphoric acid
- organic acid such as p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, citric acid, acetic acid, propionic acid
- the preferred salts and their hydrates for the purpose of the invention are edoxaban p- toluenesulfonate (also referred to as edoxaban tosylate), edoxaban p- toluenesulfonate monohydrate (also referred to as edoxaban tosylate monohydrate), edoxaban methanesulfonate and edoxaban benzenesulfonate.
- the most preferred salt for the purpose of the present invention is edoxaban p-toluenesulfonate monohydrate (also referred to as edoxaban tosylate monohydrate).
- orodispersible pharmaceutical dosage form encompasses different pharmaceutical forms, such as orodispersible tablets, orodispersible mini-tablets, orodispersible powders, amongst others.
- the preferred orodispersible pharmaceutical dosage form for the purpose of the present invention is an orodispersible tablet.
- orodispersible tablet as used herein is defined in accordance with the European Pharmacopeia, edition 10.0, page 939, as an uncoated tablet intended to be placed in the mouth where it disperses rapidly before being swallowed, more precisely orodispersible tablets disintegrate within three minutes in the disintegration test.
- orodispersible tablet is intended to be a synonym of solid oral dosage forms named as orodispersable tablet, orodisperse tablet, orally disintegrating tablet, orally disintegrated tablet, fast disintegrating tablet, fast dissolving tablet, mouthdissolving tablets, amongst others.
- complete disintegration as used herein is defined in accordance with the European Pharmacopeia, edition 10.0, page 323. Disintegration, as defined herein, does not imply complete dissolution of the dosage form or even of its active pharmaceutical ingredient.
- disintegrate as used herein is defined as the action whereby a solid dosage form is brought from a solid state to a state of complete disintegration.
- orodispersible pharmaceutical dosage forms are preferably defined as pharmaceutical dosage forms which are disintegrated or dispersed in the mouth without being capable of forming CO2 when in contact with an aqueous solution, for example saliva.
- orodispersible pharmaceutical dosage forms according to the invention in particular orodispersible tablets, do not comprise CO2-forming agents nor produce CO2 upon contact with water, neither before administration nor upon contact with an acidic aqueous solution, for example gastric juice.
- orodispersible pharmaceutical dosage forms according to the invention, in particular orodispersible tablets preferably do not encompass effervescent or effervescent-like compositions.
- dissolution profile refers to dissolution over time of edoxaban from the dosage form of the invention.
- the dissolution profile is measured in weight of dissolved edoxaban (as free base) per initial weight of edoxaban in the dosage form (calculated based on the weight of edoxaban free base), and it is expressed in weight percentage (% w/w).
- friability refers to the tendency for a tablet to chip, crumble or break during handling. The test of friability is carried out following the guidelines of the European Pharmacopeia, edition 10.0, pp. 336-337. A maximum loss of mass not greater than 1.0 % is considered acceptable for most products.
- pharmaceutically acceptable excipient refers to a substance formulated alongside with the active pharmaceutical ingredient of a medicinal product and includes all kind of pharmaceutically acceptable compounds commonly used in pharmaceutical compositions and in particular orodispersible tablets.
- pharmaceutically acceptable excipients comprise diluents, binders, disintegrants, lubricants, organic acids, sweeteners, glidants, colorants and flavor agents and mixtures thereof.
- diotin as used herein is defined as a pharmaceutical acceptable excipient that is used as diluent in pharmaceutical compositions.
- the term “diluent” comprises one or combinations of two or more selected from the group of mannitol, maltol, sorbitol, maltitol, xylitol, isomalt, erythritol, lactose, starch and its derivatives such as pregelatinized starch, cellulose and its derivatives, in particular microcrystalline cellulose, and calcium phosphate.
- Starch, cornstarch and pregelatinized starch are generally considered as diluents but they may have also some disintegrant-like properties and/or some binder-like properties. Therefore, they could be considered as multi-functional excipients.
- starch, cornstarch and pregelatinized starch are defined exclusively as diluents.
- the term “binder” and the term “disintegrant” do not encompass starch nor cornstarch nor pregelatinized starch.
- binder as used herein is defined as a pharmaceutical acceptable excipient that hold the ingredients together in pharmaceutical compositions. Binders are the agents used to increase the cohesion of the powdery particles or granules during the compression, in order to obtain pharmaceutical forms with a defined hardness. Binders ensure that tablets and granules can be formed with required mechanical strength.
- binders are defined exclusively as agents used to increase the cohesion of the powdery particles.
- orodispersible pharmaceutical dosage forms of the invention are only obtainable by a direct compression process (no granulation process is involved at all)
- the term “binder” does not encompass agents used to prepare binder solutions for manufacturing granules.
- binder shall not be understood as a “coating agent”, as a coating agent serves the purpose of coating the pharmaceutical dosage form (e.g. tablets) whereas binders as used herein in the present invention are pharmaceutical acceptable excipients that hold powdery particles together in pharmaceutical compositions.
- binders in the context of the present invention do not encompass agents which are used as coating agents or in a coating process.
- Binders in the context of the present invention, are classified into 2 classes: a) “natural binders” and b) “cellulosic polymers”.
- natural binders as used herein is defined as a pharmaceutical acceptable excipient which is a natural polymer binder or salt thereof, preferably selected from the group of alginic acid, sodium alginate, gelatin, Guar gum, Arabic gum, Candelilla wax, Carnauba wax and mixtures thereof.
- cellulosic or “cellulosic polymer” as used herein is defined as substance made from cellulose, relating to cellulose or being a chemical derivative of cellulose.
- Examples of “cellulosic polymers” are hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose and mixtures thereof.
- the preferred cellulosic polymers for the purpose of the present invention are selected from the group of consisting of: hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose.
- the most preferred are hydroxypropyl methyl cellulose and hydroxypropyl cellulose.
- disintegrant as used herein is defined as a pharmaceutical acceptable excipient that is used as disintegrant in pharmaceutical compositions.
- the term “disintegrant” comprises one or combinations of two or more selected from the group of: crospovidone, croscarmellose sodium, carmellose calcium, carmellose, calcium silicate and sodium starch glycolate and mixtures thereof.
- the term “disintegrant” preferably does not encompass “cellulosic polymers” as defined in the above paragraph - as said “cellulosic polymers” are binders (i.e. not “disintegrants ’).
- the term “disintegrant” preferably does not encompass hydroxypropyl methyl cellulose nor hydroxypropyl cellulose.
- lubricant as used herein is defined as a pharmaceutical acceptable excipient that is used as lubricant in pharmaceutical compositions.
- lubricant comprises one or combinations of two or more selected from the group of talc, sodium benzoate, sodium stearyl fumarate, calcium stearate, magnesium stearate, zinc stearate, glyceryl behenate, stearic acid and glyceryl monostearate; more particularly, such lubricant is selected from the group of sodium stearyl fumarate and magnesium stearate.
- organic acid as used herein is defined as a pharmaceutical acceptable excipient that is an organic compound that is acidic and can be used in pharmaceutical compositions.
- Acidic means that the pH in an aqueous solution is less than 7.
- Organic acids include carboxylic acids, sulfonic acids and enols, or salts thereof.
- organic acid comprises one or combinations of two or more selected from the group of adipic acid, aspartic acid, ascorbic acid, alginic acid, benzoic acid, citric acid, anhydrous citric acid, glutamic acid, succinic acid, tartaric acid, sorbic acid, lactic acid, fumaric acid, maleic acid, malonic acid, malic acid, oxalic acid, galactaric acid, gluconic acid, and glucuronic acid; more particularly, such organic acid is selected from the group of citric acid, anhydrous citric acid, tartaric acid and fumaric acid.
- sweetener as used herein is defined as a pharmaceutical acceptable excipient that is used as sweetener in pharmaceutical compositions.
- the term “sweetener” comprises one or combinations of two or more selected from the group of aspartame, potassium acesulfame (Acesulfame K), sodium saccharinate, neohesperidine dihydrochalcone, sucralose, sucrose, fructose, monoammonium glycyrrhizinate and mixtures thereof.
- glidant ’ as used herein is defined as a pharmaceutical acceptable excipient that is used as glidant in pharmaceutical compositions.
- the term “glidant” comprises one or combinations of two or more selected from the group of colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate and mixtures thereof.
- colorant as used herein is defined as a pharmaceutical acceptable excipient that is used as colorant in pharmaceutical compositions.
- the term “colorant” comprises one or combinations of two or more selected from the group of Food Yellow No.5, Food Red No. 2, and Food Blue No.2; food lake dyes, Yellow Ferric Oxide, iron sesquioxide, titanium oxide, P-carotene, riboflavin and mixtures thereof; more particularly, such colorant is selected from the group of Yellow Ferric Oxide, iron sesquioxide and titanium oxide.
- flavouring agent as used herein is defined as a pharmaceutical acceptable excipient that is used as flavouring agent in pharmaceutical compositions.
- the term “flavouring agent” comprises one or combinations of two or more selected from the group of cherry, raspberry, apricot, pear, strawberry, bitter masker, pineapple, lemon, honey, mint garden, orange, peppermint, menthol, black currant, banana, red fruits, wild berries and caramel flavour; more particularly, such flavouring agent is selected from the group of cherry, apricot, mint and honey flavour.
- an aspect of the present invention relates to an orodispersible pharmaceutical dosage form comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the amount of the binder present in the orodispersible pharmaceutical dosage form may vary between 3.5% to 15.0% w/w relative to the total weight of the dosage form, preferably between 3.5% to 12.0% w/w relative to the total weight of the dosage form, preferably of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, more preferably between 4.5% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably between 4.5% to 8.0% or 4.5% to 6.0% w/w relative to the total weight of the dosage form.
- the orodispersible pharmaceutical dosage form of the invention may comprise the binder in 3.50%, 4.00%, 4.50%, 5.00%, 5.50%, 6.00%, 6.50%, 7.00%, 7.50%, 8.00%, 8.50%, 9.00%, 9.50%, 10.00%, 10.50%, 11.00%, 11.50%, 12.00%, 12.50%, 13.00%, 13.50%, 14.00%, 14.50%, 15.00% w/w relative to the total weight of the dosage form.
- the amount of the edoxaban or the pharmaceutically acceptable salt thereof or the hydrate of said edoxaban or the hydrate of said edoxaban pharmaceutically acceptable salt per orodispersible dosage form may vary from 15 to 60 mg, based on the weight of edoxaban free base.
- the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder may range between 1.00:0.21 to 1.00:1.35, preferably of from 1.00:0.24 to 1.00:1.05, and more preferably of from 1.00:0.31 to 1.00:0.70.
- the orodispersible pharmaceutical dosage form of the invention may comprise a weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder being 1.00:0.21; 1.00:0.24; 1.00:0.25; 1.00:0.30; 1.00:0.31; 1.00:0.35; 1.00:0.40; 1.00:0.45; 1.00:0.50; 1.00:0.55,1.00:0.60; 1.00:0.65; 1.00:0.70; 1.00:0.75; 1.00:0.80; 1.00:0.85; 1.00:0.90; 1.00:0.95; 1.00:1.00; 1.00:1.05; 1.00:1.10; 1.00:1.15; 1.00:1.20; 1.00:1.25; 1.00:1.30; 1.00:1.35.
- the total amount of one or more disintegrants present in the orodispersible pharmaceutical dosage form may range between 5.0% to 20.0% w/w relative to the total weight of the dosage form , or between 7.5% to 17.5% w/w relative to the total weight of the dosage form, or between 7.5% to 12.5% w/w relative to the total weight of the dosage form, or between 12.5% to 17.5% w/w relative to the total weight of the dosage form.
- the orodispersible pharmaceutical dosage form of the invention may comprise one or more disintegrants in 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 12.5%, 13.0%, 13.5%, 14.0%, 14.5%, 15.0%, 15.5%, 16.0%, 16.5%, 17.0%, 17.5%, 18.0%, 18.5%, 19.5%, 20.0% w/w relative to the total weight of the dosage form.
- the orodispersible pharmaceutical dosage form may comprise a first disintegrant and a second disintegrant which is different from the first disintegrant.
- the weight-to-weight ratio of the first disintegrant to the second disintegrant may range of from 3.00:1.00 to 1.00:1.00, preferably of from 2.50:1.00 to 1.00:1.00, more preferably of from 2.00:1.00 to 1.00:1.00, and even more preferably of from 1.50:1.00 to 1.00:1.00.
- the orodispersible pharmaceutical dosage form of the invention may comprise a weight-to-weight ratio of the first disintegrant to the second disintegrant of 3.00:1.00; 2.90:1.00; 2.80:1.00; 2.70:1.00; 2.60:1.00; 2.50:1.00; 2.40:1.00; 2.30:1.00; 2.20:1.00; 2.10:1.00; 2.00:1.00; 1.90:1.00; 1.80:1.00; 1.70:1.00; 1.60:1.00; 1.50:1.00; 1.40:1.00; 1.30:1.00; 1.20:1.00; 1.10:1.00; 1.00:1.00.
- the orodispersible pharmaceutical dosage form may comprise an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form.
- the orodispersible pharmaceutical dosage form of the invention may comprise an organic acid at 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 12.5%, 13.0%, 13.5%, 14.0%, 14.5%, 15.0%, 15.5%, 16.0%, 16.5%, 17.0%, 17.5%, 18.0%, 18.5%, 19.0%, 19.5%, 20.0% w/w relative to the total weight of the dosage form.
- the organic acid used in the orodispersible pharmaceutical dosage form according to the invention is not particularly limited, but examples thereof include adipic acid, aspartic acid, ascorbic acid, alginic acid, benzoic acid, citric acid, anhydrous citric acid, glutamic acid, succinic acid, tartaric acid, sorbic acid, lactic acid, fumaric acid, maleic acid, malonic acid, malic acid, oxalic acid, galactaric acid, gluconic acid, and glucuronic acid; more preferably examples thereof include citric acid, anhydrous citric acid, tartaric acid and fumaric acid.
- the percentage-to -percentage ratio of organic acid to one or more disintegrants may range of from 1.00:1.875 to 1.00:17.50, preferably of from 1.00:3.125 to 1.00:17.50, and more preferably of from 1.00:4.375 to 1.00:17.50.
- the orodispersible pharmaceutical dosage form of the invention may comprise a percentage-to-percentage ratio of organic acid to one or more disintegrants of 1.00:1.875; 1.00:2.00; 1.00:2.50; 1.00:3.00; 1.00:3.125; 1.00:3.50; 1.00:4.00; 1.00:4.375; 1.00:4.50; 1.00:5.00; 1.00:5.50; 1.00:6.00; 1.00:6.50; 1.00:7.00; 1.00:7.50; 1.00:8.00; 1.00:8.50; 1.00:9.00; 1.00:9.50; 1.00:10.00; 1.00:10.50; 1.00:11.00; 1.00:11.50; 1.00:12.00; 1.00:12.50;
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said e
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said e
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said e
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxa
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispers
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispers
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispers
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, one or more disintegrants in a total amount of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, one or more disintegrants in a total amount of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, wherein the first and the second disintegrant are selected from the group consisting of: crospovidone, croscarmellose sodium, carmellose calcium, carmellose, calcium si
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, wherein the first and the second disintegrant are selected from the group consisting of: crospovidone, croscarmellose sodium, carmellose calcium, carmellose,
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-
- edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt is edoxaban comprised in the orodispersible pharmaceutical dosage form of the invention is edoxaban p-toluenesulfonate monohydrate (also referred to as edoxaban tosylate monohydrate).
- the orodispersible pharmaceutical dosage form of the invention comprises edoxaban tosylate monohydrate in the form of particles having a D(v,90) less than or equal to 50.0 pm as measured by laser light scattering.
- edoxaban tosylate monohydrate particles having a D(v, x), is defined as meaning that X% of the volume of the edoxaban tosylate monohydrate particles have a diameter equal to or less than a specified diameter.
- edoxaban tosylate monohydrate particles having a D(v, 90) less than or equal to 50.0 pm means that 90% of the volume of particles of edoxaban tosylate monohydrate have a diameter less than or equal to 50.0 pm.
- PSD particle size distributions
- the particle size distributions (PSD) of edoxaban tosylate monohydrate particles referred herein refer to particle size distributions determined using techniques available in the art, such as laser light scattering technique (e.g. by using a Malvern apparatus). Alternatively, the person skilled in the art may use other equivalent apparatus for measuring particle size distribution (PSD) of edoxaban tosylate monohydrate particles.
- API Active pharmaceutical ingredients
- D(v,90) values of less than or equal to 50.0 pm generally confer to said API poor flowability.
- the lower D(v,90) value the higher difficulty for handling it at the industrial scale, especially in terms of easiness of manipulation and health & safety for workers.
- Another drawback from API’s with low D(v,90) values is the undesired effect of segregation of the active ingredient with respect to other pharmaceutically acceptable excipients of the product along the manufacturing process, as well as low values of content of uniformity of the finished medicinal products.
- API’s with low D(v,90) values may suffer from an increased sensitivity to oxidation due to an increased surface area.
- orodispersible dosage forms according to the invention obtained by direct compression, comprising edoxaban tosylate monohydrate in the form of particles having a D(v,90) less than or equal to 50.0 pm as measured by laser light scattering, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, have excellent flowability and content uniformity, while being easy to manipulate at industrial scale (i.e. thus improving safety for workers). Furthermore, there were not observed segregation problems at an industrial scale.
- the orodispersible pharmaceutical dosage form of the invention is an orodispersible tablet.
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p- toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, and the one
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p- toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, and the one
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p- toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, and the one
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, an organic acid in an amount of 4.0% w/w relative to the total weight of the orodispersible tablet, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, wherein the organic acid is citric acid or anhydrous citric acid or tartaric acid, and wherein said orodispersible tablet is obtainable by a direct compression
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, an organic acid in an amount of 4.0% w/w relative to the total weight of the orodispersible tablet, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, wherein the organic acid is citric acid or anhydrous citric acid or tartaric acid, and wherein said orodispersible tablet is obtainable by a direct compression
- the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, an organic acid in an amount of 4.0% w/w relative to the total weight of the orodispersible tablet, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, wherein the organic acid is citric acid or anhydrous citric acid or tartaric acid, and wherein said orodispersible tablet is obtainable by a direct compression
- a second aspect of the invention relates to a direct compression process for the preparation of the orodispersible dosage form of the first aspect of the invention, which comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients; (u) blending the mixture of step (i); (in) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form.
- the process for the preparation of the orodispersible pharmaceutical dosage form of the invention comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with a binder, a disintegrant, and one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form.
- the process for the preparation of the orodispersible pharmaceutical dosage form of the invention provides an orodispersible tablet, wherein the process comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with a binder, a disintegrant, and one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible tablet.
- the process for the preparation of the orodispersible pharmaceutical dosage form of the invention provides an orodispersible tablet, wherein the process comprises the steps of: (i) mixing edoxaban p- toluenesulfonate monohydrate with a binder, a disintegrant, and one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (in) ; (v) compressing the dry powdered mixture of step (iv) to form an orodispersible tablet.
- disintegration time of currently on the market Lixiana® orally disintegrated tablets is far away from the gold-standard in the field - i.e. disintegration time in around 60 seconds or less.
- disintegration time almost double the generally accepted maximum value of around 60 seconds.
- Example 1 General manufacturing process of orodispersible tablets of the invention
- Edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), a binder and one or more disintegrants are weighed and sieved through a 1 mm mesh and further added to a suitable bin blender (Servo-lift bowl).
- the following further excipients may be optionally added to the mixture present in the bin blender: a diluent, an organic acid, a sweetener, a glidant, a colorant and a flavouring agent.
- the mixture is blended between 10 and 25 minutes at 34 rpm.
- a lubricant is weighed and sieved through a 1 mm mesh and further added to the blended mixture.
- the obtained mixture is blended 5 minutes at 34 rpm.
- the obtained dry powdered mixture is compressed in a rotatory press into the desired orodispersible tablets of the invention.
- a general composition is provided below in Table 1.
- Table 1 general composition of the orodispersible tablets of the invention
- Example 2 Qrodispersible tablets compositions according to the invention
- Formulations 2 to 5 - as representative examples according to the invention - are shown in Tables 2-3. Said Formulations 2 to 5 were similarly prepared according to the manufacturing process described in Example 1. Qrodispersible tablets of
- Formulations 2 to 5 comprised edoxaban p-toluenesulfonate monohydrate (i.e. edoxaban tosylate monohydrate) as active pharmaceutical ingredient.
- Comparative Formulation 1 which comprises 2% w/w binder
- Comparative Formulation 6 which comprises 20% w/w binder are also shown below in Tables 2-3.
- Table 2 Composition of Comparative Formulation 1, and Formulations 2 and 3.
- edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
- Table 3 Composition of Formulations 4 and 5 and Comparative Formulation 6.
- edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
- Example 3 Characterization of orodispersible tablets according to the invention: Disintegration test, hardness, thickness, friability test
- Formulations 2 to 5 (according to the invention) and Comparative Formulations 1 and 6 were also submitted for friability test in accordance with the guidelines of the European Pharmacopeia, edition 10.0, pp. 336-337. The results are shown in Table 4. Formulations 2 to 5 (according to the invention) and Comparative Formulations 1 and 6 were also characterized by their hardness and thickness.
- Table 5 Dissolution profiles of Lixiana® film-coated tablet (60 mg strength), Lixiana® orally disintegrating tablet (60 mg strength), Comparative Formulation 1 and Formulation 2.
- Table 6 Dissolution profiles of Formulations 3, 4, 5 and Comparative Formulation 6.
- edoxaban orodispersible dosage forms of the invention avoids the risk of being either suprabioequivalent or infrabioequivalent, which may affect the toxicity and/or the efficacy of said orodispersible dosage form.
- Example 5 Further orodispersible tablets compositions according to the invention
- Table 7 Composition of formulations 7 and 8.
- edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
- Table 8 Composition of formulations 9 and 10.
- edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
- Example 6 Characterization of further orodispersible tablets according to the invention: Disintegration test, hardness, thickness, friability test
- Formulations 7 to 10 were also submitted for friability test in accordance with the guidelines of the European Pharmacopeia, edition 10.0, pp. 336-337. The results are shown in Table 9. Formulations 7 to 10 were also characterized by their hardness and thickness.
- edoxaban orodispersible dosage forms of the invention avoids the risk of being either suprabioequivalent or infrabioequivalent, which may affect the toxicity and/or the efficacy of said orodispersible dosage form.
- Example 8 Forced degradation studies of formulations of the invention
- Formulations 4 and 10 were subjected to forced degradation studies under different temperature and Relative Humidity (RH) conditions.
- RH Relative Humidity
- samples of Lixiana® orally disintegrated tablets (ODT) commercially available in Japan and of Lixiana® film-coated tablets (FCT) were also analysed.
- the forced degradation studies were performed under the following conditions: (a) accelerated conditions at 40 °C/75% RH; (b) thermal degradation at 50 °C.
- impurities were quantified (See Table 11): (i) the amount of 2- (((lS,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4- c]pyridine-2-carboxamido) cyclohexyl)amino)-2-oxoacetic acid (also referred to as “oxoacetic acid impurity”), which is the main degradation impurity of edoxaban by hydrolysis; (ii) the amount of the major unknown impurity; (iii) the amount of total impurities. All values are expressed as % w/w.
- Formulations 4 and 10 are more stable under forced degradation conditions than commercially available Lixiana® orally disintegrated tablets and Lixiana® film-coated tablets.
- the total impurities present in Formulations 4 and 10 are half the amount present in the commercially available products, which are manufactured by wet-granulation.
- Example 9 Stability of formulations of the invention
- Formulation 11 has an identical quantitative composition than Formulation 10 (see Table 8), except that mint flavour (5% w/w, 21 mg) has been replaced by apricot flavour (5% w/w, 21 mg). Formulation 11 has been identically prepared than Formulation 10.
- Formulation 11 was subjected to stability studies, at conditions of 25 °C and 60% Relative Humidity (RH), and it was analyzed at 1, 2 and 3 months.
- RH Relative Humidity
- FCT Eixiana® film-coated tablets
- impurities were quantified (See Table 12): (i) the amount of 2-(((lS,2R,4S)-4-(dimethylcarbamoyl)-2-(5- methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido) cyclo hexyl) amino)-2-oxoacetic acid (also referred to as “oxoacetic acid impurity”), which is the main degradation impurity of edoxaban by hydrolysis; (ii) the amount of the major unknown impurity; (iii) the amount of total impurities. All values are expressed as % w/w.
- Table 12 Stability studies under 25 °C and 60% RH.
- ND stands for non-detected
- Formulation 11 which was prepared by a direct compression process is more stable, under stability studies at 25 °C and 60% RH, than commercially available Lixiana® film-coated tablet.
- major unknown impurity and total number of impurities was significantly lower in Formulation 11 according to the present invention than commercially available product, which is manufactured by wet-granulation.
- Example 10 Manufacturing time comparison between orodispersible formulations manufactured according to the invention and orodispersible formulations of the prior art
- the manufacturing time needed for obtaining Formulation 10 was compared to the manufacturing time needed for obtaining formulation disclosed in [example 1-2] of EP3549585 Al (See Table 13).
- Formulation 10 having a quantitative formulation as described in Example 5 (Table 8), was manufactured according to process described in Example 1 - all the following components were separately weighed and sieved through a 1 mm mesh and further added to a bin blender (Servo-lift bowl): 404.00 g of edoxaban tosylate monohydrate, 645.30 g of D-mannitol, 315.00 g of starch, 210.00 g of crospovidone, 120.00 g of hydroxypropyl methyl cellulose (HPMC), 157.50 g of sodium croscarmellose, 15.40 g of aspartame, 84.00 g of citric acid, 10.50 of colloidal silicone dioxide, 1.80 g of yellow ferric oxide and 150.00 g of mint flavour.
- a bin blender 404.00 g of edoxaban tosylate monohydrate, 645.30 g of D-mannitol, 315.00 g of starch, 210.00 g of crospovidone, 120.00 g
- Formulation disclosed in [example 1-2] of EP3549585 Al was prepared according to the described process therein (i.e. obtaining two different types of granules after two distinct wet- granulation processes). Weighing and adding all components to the granulator dryer equipment took 60 minutes. Granulation for obtaining the drug-containing granules (i.e. edoxaban-containing granules) took 60 minutes, plus another 60 minutes for drying. Then, weighing and adding all components to the equipment for the second granulation took 60 minutes. Granulation for obtaining the rapidly disintegrating granules took 60 minutes, plus another 60 minutes for drying. The drug-containing granules and rapidly disintegrating granules were mixed and blended for 15 minutes.
- edoxaban-containing granules i.edoxaban-containing granules
- the drug-containing granules and rapidly disintegrating granules were mixed and blended for 15 minutes.
- magnesium stearate was weighed and sieved through a 1 mm mesh and further added to the blended mixture. This took 5 minutes.
- the obtained mixture, containing the magnesium stearate was blended for 5 minutes.
- the obtained dry powdered mixture was compressed in a rotatory press into orodispersible tablets, requiring 180 minutes.
- the time employed in the manufacturing of a complete batch of edoxaban orodispersible tablets according to the invention is less than half as the one required for manufacturing of a complete batch of edoxaban orodispersible tablets according to EP3549585 Al.
- direct compression process of the invention provides an improvement in time of manufacturing, leading to a reduction of in economic and energetic manufacturing costs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an orodispersible pharmaceutical dosage form of edoxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.
Description
AN ORODISPERSIBLE PHARMACEUTICAL DOSAGE FORM OF EDOXABAN
RELATED APPLICATIONS
This application is related to Indian Provisional Application No. IN202121053646 filed on 22nd November, 2021 and is incorporated herein in its entirety.
FIELD OF THE INVENTION
The present invention relates to an orodispersible pharmaceutical dosage form of edoxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.
BACKGROUND OF THE INVENTION
Edoxaban is represented by the structural formula (I) and its chemical name is (N'-(5-chloropyridin-2-yl)-N-[(lS,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl- 6,7-dihydro-4H-[l,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl] oxamide).
Formula (I)
In Europe, edoxaban (Lixiana®) was approved by the European Medicines Agency (EMA) in June 2015, whereas in the US, the Food and Drug Administration (FDA) approved edoxaban (Savaysa®) in January 2015. Edoxaban is indicated both in EU and the US in: (i) prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age > 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA), and (ii) treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults. Lixiana®/Savaysa® is commercially available both in Europe and the US as immediate release film- coated tablets in 15, 30 and 60 mg strengths (based on edoxaban free base). The used pharmaceutically acceptable salt of edoxaban in Lixiana® /Savaysa® is edoxaban tosylate monohydrate.
Edoxaban immediate-release film-coated tablets are the only available commercial dosage form in Europe (Lixiana®) and in the US (Savaysa®). These conventional tablets need to be swallowed - meaning that patients in therapy should be able to perform the action of swallowing correctly. However, swallowing may prove difficult for some category of patients, for example, for elderly patients or pediatric patients, or for patients who barely cooperate with medical personnel because of progression of disabling diseases. In these clinical situations the patient has difficulty in swallowing, and therefore it would be advisable to replace the tablets that are to be swallowed with water with other oral dosages forms in which swallowing is made easier.
A particular solid pharmaceutical dosage form that rapidly disintegrates are orodispersible tablets (also named orally disintegrated tablet (ODT) or fast disintegrating tablets), which do not require water, and hence can be consumed in situations where patients require an easy-to-administer dosage form. Orodispersible tablets are an improved dosage form with respect to conventional tablets, as they are not required to be swallowed and are in line with the current
fast-paced modern lifestyle. Furthermore, orodispersible tablets are especially suitable for patients suffering from dysphagia, wherein closure of the glottis and simultaneous contraction of the muscles of the larynx do not propel adequately the conventional tablet that needs to be swallowed.
In this regard, there are disclosures in the prior art directed to orodispersible pharmaceutical compositions comprising edoxaban. However, these suffer from the serious drawbacks of being manufactured by wet-granulation processes which require several processing steps and long manufacturing times, thus making the overall process lengthy and with high cost. Moreover, orodispersible edoxaban compositions known from the prior art made by wet-granulation techniques tend to deliver finished drug formulations with variability with respect to the dissolution rate of edoxaban. Another limitation of the known orodispersible edoxaban compositions is their stability, as during wet-granulation steps edoxaban is subjected to humidity conditions (water or other solvents) or to high temperatures required for drying obtained edoxaban granules. Such harsh conditions result in stability problems of the manufactured orodispersible edoxaban compositions.
For example, EP3549585 discloses orally disintegrating tablets comprising edoxaban, an organic acid, 0.1 to 2.0% w/w of a water-soluble polymer relative to the total weight of the disintegrating tablet, and a disintegrant. Disclosed examples therein, having adequate physicochemical properties such as disintegration time and hardness, were all manufactured by compressing two different types of granules obtained after two distinct wet-granulation processes, i.e. in a first step, edoxaban-containing granules (referred to as “drug-containing granules”) were obtained by wet-granulating a mixture comprising the active ingredient with other excipients, employing as a granulating agent an aqueous solution containing 0.1 to 2.0% w/w of a water-soluble polymer, whereas a second step consisted of wet-granulating pharmaceutically acceptable excipients, which yielded a second type of granules (referred to as “rapidly disintegrating
granules ’). The final step consisted of mixing of both edoxaban-containmg type granules and rapidly disintegrating granules with further excipients, and compression to obtain orally disintegrated tablets.
EP3815686 discloses edoxaban granular preparations which are manufactured by two separated and independent granulation processes which yield two different types of granules. Specifically, a first type of granules, which are edoxaban- containing granules (referred to as “drug-containing granules”) are obtained by wet-granulating a mixture of edoxaban with other excipients. In a subsequent and separated step, a second type of granules (referred to as “drug-free granules”) are obtained by wet-granulating a mixture of xylitol or sorbitol with carmellose sodium, employing as a granulating agent either an aqueous solution containing carmellose sodium or water alone.
In Japan, edoxaban (Lixiana®) was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on April 2011. Edoxaban is approved in Japan for the same mentioned indications as for Europe and US. Additionally, it is approved in Japan for the prevention of venous thromboembolism (VTE) in patients undergoing any of the following orthopedic surgeries for the lower limbs: total knee replacement, total hip replacement, and hip fracture surgery.
Besides being available in the form of conventional film-coated tablets, edoxaban (Lixiana®) is also marketed as orally disintegrated tablets in 15, 30 and 60 mg strengths (based on edoxaban free base). ODT’s are distinguished from conventional sublingual tablets, buccal tablets and lozenges by their fast disintegration time in the oral cavity, which generally takes around 60 seconds or less. In fact, the FDA Center for Drug Evaluation and Research (CDER) defines orodispersible tablets as: “A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue”. Therefore, it is commonly accepted in the art of developing/manufacturing orodispersible tablets that such tablets, when placed in
the mouth, should disintegrate in less than one minute - otherwise, if disintegration takes longer, the attractiveness of orodispersible tablets is lost, as the taste buds of the patients’ tongue and other receptors of the oral cavity are extensively exposed to a direct contact with the active ingredient. Moreover, for those patients who are travelling or which have limited access to water, it may be discomfortable to take an orodispersible tablet which does not disintegrate rapidly (i.e. in less than one minute). In this regard, it has been observed that 60 mg strength of Lixiana® orally disintegrated tablets, which is commercially available in Japan, takes longer than 60 seconds to disintegrate completely. This may result in a lower acceptability of said orodispersible dosage form, which ultimately may impact adherence to the treatment and worsening of the clinical pattern.
Edoxaban is a Class 4 substance according to the Biopharmaceuticals Classification System (BCS), with low aqueous solubility and low permeability. Edoxaban exhibits high solubility in a strong acidic aqueous solution, but its solubility decreases in a neutral pH aqueous solution. Lixiana® film-coated tablets and orally disintegrating tablets release edoxaban in immediate-release manner. In particular, it has been determined that both commercially available forms of Lixiana® (conventional tablets and orodispersible tablets) release 85% or more of edoxaban within 15 minutes at pH=1.2.
When developing new orodispersible pharmaceutical dosage forms, it should be borne in mind that it is a standard requirement by regulatory agencies to prove strict bioequivalence criteria of said newly developed orodispersible pharmaceutical dosage form versus the conventional film coated tablet of the reference product. For instance, in Europe, according to the Guideline for Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. l/Corr., 2010), if it cannot be demonstrated that the active ingredient is not absorbed in the oral cavity, bioequivalence for new developed orodispersible tablets must be evaluated in
human studies. Therefore, said requirement of bioequivalence poses considerable challenges for the development of new orodispersible tablets.
Therefore, in view of the prior art, there is the need to provide for edoxaban orodispersible pharmaceutical dosage forms having overall improved characteristics. In this regard, there is room for improvement in the prior art for providing edoxaban orodispersible compositions obtainable by a fast, straightforward and low-cost process while having at the same time improved disintegration time, stability, friability and hardness. Furthermore, there is the need to provide for edoxaban orodispersible pharmaceutical dosage forms which, from a regulatory standpoint, exhibit reliable and adequate dissolution profile of edoxaban for resulting in being bioequivalent to Lixiana® immediate-release film-coated tablets.
SUMMARY OF THE INVENTION
The inventors of the present invention have been capable of designing new orodispersible pharmaceutical dosage forms comprising edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
By manufacturing orodispersible pharmaceutical dosage form of the invention by a direct compression process, the manufacture of a complete batch of edoxaban orodispersible tablets is made within few hours, thus allowing complete
production in a single-day shift at the manufacturing site. This represents an improvement with respect to wet-granulation manufacturing processes known in the art, which require more than the standard 8-hours shift in a manufacturing site. In other words, the time employed in the manufacturing of a complete batch of edoxaban orodispersible tablets according to the invention (i.e. by a direct compression process) is less than half as the one required for manufacturing of a complete batch of edoxaban orodispersible tablets according to EP3549585 Al. Thus, direct compression process of the invention provides an improvement in time of manufacturing, leading to a reduction of in economic and energetic manufacturing costs.
Even more, the inventors have surprisingly found that orodispersible pharmaceutical dosage forms of the invention, obtained by direct compression, comprising edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, also have overall improved technical characteristics as summarised hereinafter.
Despite the teaching away comments from EP3549585, whereby it is disclosed that if the content of a water-soluble polymer (i.e. a type of binder) is too high - meaning above 3.0% w/w relative to the total weight of the edoxaban orodispersible dosage form - suspending of the final tablet takes too much time and therefore it is not suitable as an orally disintegrating tablet, the inventors have unexpectedly found that orodispersible pharmaceutical dosage forms of the invention, which comprise a binder in high amount (i.e. from 3.5% to 15.0% w/w relative to the total weight of the dosage form), indeed satisfactorily disintegrate rapidly, in particular in less than two minutes, particularly in less than one minute and a half, more particularly in less than one minute, and even more particularly in less than 55 seconds. In particular, the dosage forms of the
invention disintegrate in the tune range of from two minutes and 5 seconds, preferably in the time range of from one minute and 40 seconds and 10 seconds, more preferably in the time range of from one minute and 30 seconds and 15 seconds, and even more preferably in the time range of from one minute and 15 seconds and 20 seconds.
This disintegration time represents an improvement with respect to 60 mg strength commercially available Lixiana® orally disintegrated tablets, which take longer than one minute and a half to completely disintegrate and which are manufactured by compressing two different types of granules (“edoxaban- containing granules” and “rapidly disintegrating granules”) obtained after two distinct and separated wet-granulation processes. Such an improved disintegration time demonstrates that edoxaban orodispersible dosage forms of the invention are suitable dosage forms for replacing conventional Lixiana® film-coated tablets in the treatment of: (i) prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, and/or (ii) treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and/or (iii) prevention of venous thromboembolism (VTE) in patients undergoing any of the following orthopedic surgeries for the lower limbs: total knee replacement, total hip replacement, and hip fracture surgery.
Edoxaban orodispersible pharmaceutical dosage forms of the invention have adequate hardness and low friability, which are important advantages in order to withstand physical shocks along manufacturing process and for storage and handling transportation. Moreover, edoxaban orodispersible pharmaceutical dosage forms of the invention have an improved stability with respect to commercially available Lixiana® orally disintegrated tablets and Lixiana® film- coated tablets. By manufacturing the orodispersible forms of the invention via direct compression process within the presence of a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant,
and one or more further pharmaceutically acceptable excipients, formation of degradation products can surprisingly be prevented over time. Particularly, edoxaban orodispersible compositions of the invention comply with the strict criteria of impurities limit specifications required by the European or Japanese regulatory agencies.
Furthermore, edoxaban orodispersible pharmaceutical dosage forms of the invention allow to provide reliable and adequate dissolution profile of edoxaban, thus releasing edoxaban in a sufficiently equivalent manner for being bioequivalent to immediate-release film-coated tablets of Lixiana®. In this regard, edoxaban orodispersible compositions of the invention rapidly release at least 85% or more of edoxaban within 15 minutes at pH=1.2. By having such dissolution profile, and thus being sufficiently equivalent to currently marketed Lixiana® conventional tablets, edoxaban orodispersible dosage forms of the invention avoids the risk of being either suprabioequivalent or infrabioequivalent, which may affect the toxicity and/or the efficacy of said orodispersible dosage form. Therefore, orodispersible pharmaceutical dosage forms of the invention constitute a valuable therapeutic tool in the field of anticoagulant medicinal products.
Advantageously, the inventors have also unexpectedly found that the preferable presence of two different pharmaceutically acceptable disintegrants in the orodispersible pharmaceutical dosage form of the invention provides a synergistic effect in terms of disintegration time, as well as in terms of hardness and friability. In other words, the interaction of two different pharmaceutically acceptable disintegrants in the orodispersible tablets of the invention achieves an improved disintegration time, hardness, friability and stability while providing an adequate dissolution profile of edoxaban.
Thus, a first aspect of the present invention relates to an orodispersible pharmaceutical dosage form comprising edoxaban or a pharmaceutically
acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
A second aspect of the invention relates to a direct compression process for the preparation of the orodispersible dosage form of the first aspect of the invention, which comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form.
A third aspect of the invention relates to the orodispersible dosage form of the fist aspect of the invention for use in: a) prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age > 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA); and/or b) treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults; and/or c) prevention of venous thromboembolism (VTE) in patients undergoing any of the following orthopedic surgeries for the lower limbs: total knee replacement, total hip replacement, and hip fracture surgery.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the dissolution profiles of: (i) film-coated tablet of Lixiana® (60 mg strength), (ii) a Japanese commercially available orally disintegrating tablet Lixiana® (60 mg strength), (iii) Comparative Formulation 1, (iv) Formulations 2, 3 and 4. Said dissolution profiles were measured according to the following dissolution method: (i) USP Apparatus II (paddle); (ii) speed = 50 rpm; (iii) pH=1.2; (iv) volume = 900 mL; (v) temperature = 37 °C; (vi) N=6. Percentage of dissolution (%D) is expressed in % w/w; time (t) is expressed in minutes (min).
Figure 2 shows the dissolution profiles of: (i) Comparative Formulation 6, (ii) Formulations 5, 7, 8, 9 and 10. Said dissolution profiles were measured according to the following dissolution method: (i) USP Apparatus II (paddle); (ii) speed = 50 rpm; (iii) pH=1.2; (iv) volume = 900 mL; (v) temperature = 37 °C; (vi) N=6. Percentage of dissolution (%D) is expressed in % w/w; time (t) is expressed in minutes (min).
DETAILED DESCRIPTION
The term “active ingredient” or “API” as used herein refers to a pharmaceutically active molecule (e.g. edoxaban) as well as its pharmaceutically acceptable and therapeutically active salts, hydrates, esters, amides, prodrugs, metabolites, enantiomers, polymorphs, analogs, etc. that induce a desired pharmacological or physiological effect. Terms like "active", "active agent", "active pharmaceutical ingredient", "active substance", "drug substance", "active drug" may be used synonymously for "active ingredient".
The term “edoxaban” as used herein corresponds to the International Nonproprietary Name (INN) for (N'-(5-chloropyridin-2-yl)-N-[(lS,2R,4S)-4- (dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[l,3]thiazolo[5,4-c]pyridine- 2-carbonyl)amino]cyclohexyl]oxamide) but also as their pharmaceutically
acceptable salts and/or hydrates. Pharmaceutically acceptable salts of edoxaban and their hydrates comprise any of a broad range of inorganic and organic acids. Examples of such salts include acid addition salts with a mineral acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, or phosphoric acid, and those with an organic acid such as p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, citric acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, tartaric acid, maleic acid, malic acid, fumaric acid, mandelic acid. The preferred salts and their hydrates for the purpose of the invention are edoxaban p- toluenesulfonate (also referred to as edoxaban tosylate), edoxaban p- toluenesulfonate monohydrate (also referred to as edoxaban tosylate monohydrate), edoxaban methanesulfonate and edoxaban benzenesulfonate. Among them, the most preferred salt for the purpose of the present invention is edoxaban p-toluenesulfonate monohydrate (also referred to as edoxaban tosylate monohydrate).
The term “orodispersible pharmaceutical dosage form” as used herein encompasses different pharmaceutical forms, such as orodispersible tablets, orodispersible mini-tablets, orodispersible powders, amongst others. The preferred orodispersible pharmaceutical dosage form for the purpose of the present invention is an orodispersible tablet.
The term “orodispersible tablet” as used herein is defined in accordance with the European Pharmacopeia, edition 10.0, page 939, as an uncoated tablet intended to be placed in the mouth where it disperses rapidly before being swallowed, more precisely orodispersible tablets disintegrate within three minutes in the disintegration test. In accordance with this definition the term orodispersible tablet is intended to be a synonym of solid oral dosage forms named as orodispersable tablet, orodisperse tablet, orally disintegrating tablet, orally disintegrated tablet, fast disintegrating tablet, fast dissolving tablet, mouthdissolving tablets, amongst others.
The term “disintegration test ’ as used herein is defined in accordance with Test A of the European Pharmacopeia (edition 10.0, page 323), water having pH=7, at 37°C and 30 cycles per minute. The term “complete disintegration” as used herein is defined in accordance with the European Pharmacopeia, edition 10.0, page 323. Disintegration, as defined herein, does not imply complete dissolution of the dosage form or even of its active pharmaceutical ingredient.
The term “disintegrate” as used herein is defined as the action whereby a solid dosage form is brought from a solid state to a state of complete disintegration.
Thus, in the context of the present invention, orodispersible pharmaceutical dosage forms, including orodispersible tablets, are preferably defined as pharmaceutical dosage forms which are disintegrated or dispersed in the mouth without being capable of forming CO2 when in contact with an aqueous solution, for example saliva. In other words, orodispersible pharmaceutical dosage forms according to the invention, in particular orodispersible tablets, do not comprise CO2-forming agents nor produce CO2 upon contact with water, neither before administration nor upon contact with an acidic aqueous solution, for example gastric juice. For the avoidance of any doubt, orodispersible pharmaceutical dosage forms according to the invention, in particular orodispersible tablets, preferably do not encompass effervescent or effervescent-like compositions.
The term “dissolution profile” as used herein refers to dissolution over time of edoxaban from the dosage form of the invention. Hereinafter, the dissolution profile is measured in weight of dissolved edoxaban (as free base) per initial weight of edoxaban in the dosage form (calculated based on the weight of edoxaban free base), and it is expressed in weight percentage (% w/w). Unless otherwise stated, hereinafter, the dissolution profiles have been measured under two different pH conditions: a) at pH=1.2; and b) at pH=6.8. Dissolution profile measured at pH=1.2 are determined using a USP Apparatus II (paddle), placing
the dosage form in 900 mL (for edoxaban strengths of 60 mg and 30 mg) and in 500 mL (for edoxaban strength of 15 mg), at 37 °C, stirring at 50 revolutions per minute and N=6. Dissolution profile measured at pH=6.8 are determined using a USP Apparatus II (paddle), placing the dosage form in 900 mL (for edoxaban strengths of 60 mg and 30 mg) and in 500 mL (for edoxaban strength of 15 mg), at 37 °C, stirring at 50 revolutions per minute and N=6.
The term “edoxaban immediately release” or “edoxaban released in immediate- release manner” as used herein refer to dissolution of at least 85% of edoxaban as free base, expressed in weight percentage (% w/w) per initial weight of edoxaban in the dosage form (calculated based on the weight of edoxaban free base), within 15 minutes at pH=1.2, measured as described in the above paragraph.
The term “friability” as used herein refers to the tendency for a tablet to chip, crumble or break during handling. The test of friability is carried out following the guidelines of the European Pharmacopeia, edition 10.0, pp. 336-337. A maximum loss of mass not greater than 1.0 % is considered acceptable for most products.
The term “pharmaceutically acceptable excipient” (also named as “excipients”) refers to a substance formulated alongside with the active pharmaceutical ingredient of a medicinal product and includes all kind of pharmaceutically acceptable compounds commonly used in pharmaceutical compositions and in particular orodispersible tablets. The term “pharmaceutically acceptable excipients” comprise diluents, binders, disintegrants, lubricants, organic acids, sweeteners, glidants, colorants and flavor agents and mixtures thereof.
The term “diluent” as used herein is defined as a pharmaceutical acceptable excipient that is used as diluent in pharmaceutical compositions. The term “diluent” comprises one or combinations of two or more selected from the group
of mannitol, maltol, sorbitol, maltitol, xylitol, isomalt, erythritol, lactose, starch and its derivatives such as pregelatinized starch, cellulose and its derivatives, in particular microcrystalline cellulose, and calcium phosphate.
Starch, cornstarch and pregelatinized starch are generally considered as diluents but they may have also some disintegrant-like properties and/or some binder-like properties. Therefore, they could be considered as multi-functional excipients. However, in the context of the present invention, starch, cornstarch and pregelatinized starch are defined exclusively as diluents. In other words, in the context of the present invention, the term “binder” and the term “disintegrant” do not encompass starch nor cornstarch nor pregelatinized starch.
The term “binder” as used herein is defined as a pharmaceutical acceptable excipient that hold the ingredients together in pharmaceutical compositions. Binders are the agents used to increase the cohesion of the powdery particles or granules during the compression, in order to obtain pharmaceutical forms with a defined hardness. Binders ensure that tablets and granules can be formed with required mechanical strength.
However, in the context of the present invention, binders are defined exclusively as agents used to increase the cohesion of the powdery particles. In other words, taking into account that orodispersible pharmaceutical dosage forms of the invention are only obtainable by a direct compression process (no granulation process is involved at all), the term “binder” does not encompass agents used to prepare binder solutions for manufacturing granules.
Additionally, in the context of the present invention, the term “binder” shall not be understood as a “coating agent”, as a coating agent serves the purpose of coating the pharmaceutical dosage form (e.g. tablets) whereas binders as used herein in the present invention are pharmaceutical acceptable excipients that hold powdery particles together in pharmaceutical compositions. In other words, the
term “binder ’ in the context of the present invention do not encompass agents which are used as coating agents or in a coating process.
Binders, in the context of the present invention, are classified into 2 classes: a) “natural binders” and b) “cellulosic polymers”.
The term “natural binders” as used herein is defined as a pharmaceutical acceptable excipient which is a natural polymer binder or salt thereof, preferably selected from the group of alginic acid, sodium alginate, gelatin, Guar gum, Arabic gum, Candelilla wax, Carnauba wax and mixtures thereof.
The term “cellulosic” or “cellulosic polymer” as used herein is defined as substance made from cellulose, relating to cellulose or being a chemical derivative of cellulose. Examples of “cellulosic polymers” are hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose and mixtures thereof. The preferred cellulosic polymers for the purpose of the present invention are selected from the group of consisting of: hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose. The most preferred are hydroxypropyl methyl cellulose and hydroxypropyl cellulose.
The term “disintegrant” as used herein is defined as a pharmaceutical acceptable excipient that is used as disintegrant in pharmaceutical compositions. The term “disintegrant” comprises one or combinations of two or more selected from the group of: crospovidone, croscarmellose sodium, carmellose calcium, carmellose, calcium silicate and sodium starch glycolate and mixtures thereof. For the avoidance of any doubt, in the context of the present invention, the term “disintegrant” preferably does not encompass “cellulosic polymers” as defined in the above paragraph - as said “cellulosic polymers” are binders (i.e. not
“disintegrants ’). In other words, m the context of the present invention, the term “disintegrant” preferably does not encompass hydroxypropyl methyl cellulose nor hydroxypropyl cellulose.
The term “lubricant” as used herein is defined as a pharmaceutical acceptable excipient that is used as lubricant in pharmaceutical compositions. The term “lubricant” comprises one or combinations of two or more selected from the group of talc, sodium benzoate, sodium stearyl fumarate, calcium stearate, magnesium stearate, zinc stearate, glyceryl behenate, stearic acid and glyceryl monostearate; more particularly, such lubricant is selected from the group of sodium stearyl fumarate and magnesium stearate.
The term “organic acid” as used herein is defined as a pharmaceutical acceptable excipient that is an organic compound that is acidic and can be used in pharmaceutical compositions. Acidic means that the pH in an aqueous solution is less than 7. Organic acids include carboxylic acids, sulfonic acids and enols, or salts thereof. The term “organic acid” comprises one or combinations of two or more selected from the group of adipic acid, aspartic acid, ascorbic acid, alginic acid, benzoic acid, citric acid, anhydrous citric acid, glutamic acid, succinic acid, tartaric acid, sorbic acid, lactic acid, fumaric acid, maleic acid, malonic acid, malic acid, oxalic acid, galactaric acid, gluconic acid, and glucuronic acid; more particularly, such organic acid is selected from the group of citric acid, anhydrous citric acid, tartaric acid and fumaric acid.
The term “sweetener” as used herein is defined as a pharmaceutical acceptable excipient that is used as sweetener in pharmaceutical compositions. The term “sweetener” comprises one or combinations of two or more selected from the group of aspartame, potassium acesulfame (Acesulfame K), sodium saccharinate, neohesperidine dihydrochalcone, sucralose, sucrose, fructose, monoammonium glycyrrhizinate and mixtures thereof.
The term “glidant ’ as used herein is defined as a pharmaceutical acceptable excipient that is used as glidant in pharmaceutical compositions. The term “glidant” comprises one or combinations of two or more selected from the group of colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate and mixtures thereof.
The term “colorant” as used herein is defined as a pharmaceutical acceptable excipient that is used as colorant in pharmaceutical compositions. The term “colorant” comprises one or combinations of two or more selected from the group of Food Yellow No.5, Food Red No. 2, and Food Blue No.2; food lake dyes, Yellow Ferric Oxide, iron sesquioxide, titanium oxide, P-carotene, riboflavin and mixtures thereof; more particularly, such colorant is selected from the group of Yellow Ferric Oxide, iron sesquioxide and titanium oxide.
The term “flavouring agent” as used herein is defined as a pharmaceutical acceptable excipient that is used as flavouring agent in pharmaceutical compositions. The term “flavouring agent” comprises one or combinations of two or more selected from the group of cherry, raspberry, apricot, pear, strawberry, bitter masker, pineapple, lemon, honey, mint garden, orange, peppermint, menthol, black currant, banana, red fruits, wild berries and caramel flavour; more particularly, such flavouring agent is selected from the group of cherry, apricot, mint and honey flavour.
As it is mentioned above, an aspect of the present invention relates to an orodispersible pharmaceutical dosage form comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a
pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
According to the invention, the amount of the binder present in the orodispersible pharmaceutical dosage form may vary between 3.5% to 15.0% w/w relative to the total weight of the dosage form, preferably between 3.5% to 12.0% w/w relative to the total weight of the dosage form, preferably of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, more preferably between 4.5% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably between 4.5% to 8.0% or 4.5% to 6.0% w/w relative to the total weight of the dosage form. The orodispersible pharmaceutical dosage form of the invention may comprise the binder in 3.50%, 4.00%, 4.50%, 5.00%, 5.50%, 6.00%, 6.50%, 7.00%, 7.50%, 8.00%, 8.50%, 9.00%, 9.50%, 10.00%, 10.50%, 11.00%, 11.50%, 12.00%, 12.50%, 13.00%, 13.50%, 14.00%, 14.50%, 15.00% w/w relative to the total weight of the dosage form.
According to the invention, the amount of the edoxaban or the pharmaceutically acceptable salt thereof or the hydrate of said edoxaban or the hydrate of said edoxaban pharmaceutically acceptable salt per orodispersible dosage form may vary from 15 to 60 mg, based on the weight of edoxaban free base.
According to the invention, the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder may range between 1.00:0.21 to 1.00:1.35, preferably of from 1.00:0.24 to 1.00:1.05, and more preferably of from 1.00:0.31 to 1.00:0.70. The orodispersible pharmaceutical dosage form of the invention may comprise a weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder being 1.00:0.21; 1.00:0.24; 1.00:0.25; 1.00:0.30; 1.00:0.31; 1.00:0.35; 1.00:0.40; 1.00:0.45; 1.00:0.50; 1.00:0.55,1.00:0.60; 1.00:0.65; 1.00:0.70; 1.00:0.75;
1.00:0.80; 1.00:0.85; 1.00:0.90; 1.00:0.95; 1.00:1.00; 1.00:1.05; 1.00:1.10; 1.00:1.15; 1.00:1.20; 1.00:1.25; 1.00:1.30; 1.00:1.35.
According to the invention, the total amount of one or more disintegrants present in the orodispersible pharmaceutical dosage form may range between 5.0% to 20.0% w/w relative to the total weight of the dosage form , or between 7.5% to 17.5% w/w relative to the total weight of the dosage form, or between 7.5% to 12.5% w/w relative to the total weight of the dosage form, or between 12.5% to 17.5% w/w relative to the total weight of the dosage form. The orodispersible pharmaceutical dosage form of the invention may comprise one or more disintegrants in 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 12.5%, 13.0%, 13.5%, 14.0%, 14.5%, 15.0%, 15.5%, 16.0%, 16.5%, 17.0%, 17.5%, 18.0%, 18.5%, 19.5%, 20.0% w/w relative to the total weight of the dosage form.
According to the invention, the orodispersible pharmaceutical dosage form may comprise a first disintegrant and a second disintegrant which is different from the first disintegrant. According to the invention, the weight-to-weight ratio of the first disintegrant to the second disintegrant may range of from 3.00:1.00 to 1.00:1.00, preferably of from 2.50:1.00 to 1.00:1.00, more preferably of from 2.00:1.00 to 1.00:1.00, and even more preferably of from 1.50:1.00 to 1.00:1.00. The orodispersible pharmaceutical dosage form of the invention may comprise a weight-to-weight ratio of the first disintegrant to the second disintegrant of 3.00:1.00; 2.90:1.00; 2.80:1.00; 2.70:1.00; 2.60:1.00; 2.50:1.00; 2.40:1.00; 2.30:1.00; 2.20:1.00; 2.10:1.00; 2.00:1.00; 1.90:1.00; 1.80:1.00; 1.70:1.00; 1.60:1.00; 1.50:1.00; 1.40:1.00; 1.30:1.00; 1.20:1.00; 1.10:1.00; 1.00:1.00.
According to the invention, the orodispersible pharmaceutical dosage form may comprise an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in
an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form.
More preferably, the orodispersible pharmaceutical dosage form of the invention may comprise an organic acid at 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 12.5%, 13.0%, 13.5%, 14.0%, 14.5%, 15.0%, 15.5%, 16.0%, 16.5%, 17.0%, 17.5%, 18.0%, 18.5%, 19.0%, 19.5%, 20.0% w/w relative to the total weight of the dosage form.
The organic acid used in the orodispersible pharmaceutical dosage form according to the invention is not particularly limited, but examples thereof include adipic acid, aspartic acid, ascorbic acid, alginic acid, benzoic acid, citric acid, anhydrous citric acid, glutamic acid, succinic acid, tartaric acid, sorbic acid, lactic acid, fumaric acid, maleic acid, malonic acid, malic acid, oxalic acid, galactaric acid, gluconic acid, and glucuronic acid; more preferably examples thereof include citric acid, anhydrous citric acid, tartaric acid and fumaric acid.
According to the invention, the percentage-to -percentage ratio of organic acid to one or more disintegrants may range of from 1.00:1.875 to 1.00:17.50, preferably of from 1.00:3.125 to 1.00:17.50, and more preferably of from 1.00:4.375 to 1.00:17.50. The orodispersible pharmaceutical dosage form of the invention may comprise a percentage-to-percentage ratio of organic acid to one or more disintegrants of 1.00:1.875; 1.00:2.00; 1.00:2.50; 1.00:3.00; 1.00:3.125; 1.00:3.50; 1.00:4.00; 1.00:4.375; 1.00:4.50; 1.00:5.00; 1.00:5.50; 1.00:6.00; 1.00:6.50; 1.00:7.00; 1.00:7.50; 1.00:8.00; 1.00:8.50; 1.00:9.00; 1.00:9.50; 1.00:10.00; 1.00:10.50; 1.00:11.00; 1.00:11.50; 1.00:12.00; 1.00:12.50;
1.00:13.00; 1.00:13.50; 1.00:14.00; 1.00:14.50; 1.00:15.00; 1.00:15.50;
1.00:16.00; 1.00:16.50; 1.00:17.00; 1.00:17.50.
In an embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a
dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w
relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a
dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban
pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban
pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and
one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-
to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free
base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.24 to 1.00:1.05, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible
pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight- to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.31 to 1.00:0.70, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a
dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is
obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl
cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a
disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically
acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically
acceptable salt, the cellulosic polymer, the disin tegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl
methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disin tegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a
disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical
dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disin tegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage
form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl
methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disin tegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15
to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically
acceptable salt, the cellulosic polymer, the disin tegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, one or more disintegrants in a total amount of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the one or more disintegrants, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, one or more disintegrants in a total amount of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form
is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the one or more disintegrants, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the first disintegrant, the second disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from
5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to- weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the first disintegrant, the second disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the first disintegrant, the second disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the first disintegrant, the second disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, wherein the first and the second disintegrant are
selected from the group consisting of: crospovidone, croscarmellose sodium, carmellose calcium, carmellose, calcium silicate and sodium starch glycolate, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the first disintegrant, the second disintegrant, and the one or more further pharmaceutically acceptable excipients.
In an even more particular embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, a first disintegrant and a second further disintegrant which is different from the first disintegrant, wherein the total amount of both the first and the second disintegrant is of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, wherein the first and the second disintegrant are selected from the group consisting of: crospovidone, croscarmellose sodium, carmellose calcium, carmellose, calcium silicate and sodium starch glycolate, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said
edoxaban pharmaceutically acceptable salt, the binder, the first disintegrant, the second disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form, and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w
relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight
of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically
acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in
an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to
1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically
acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to
15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the
total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.21 to 1.00:1.35, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl
cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the
disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically
acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.24 to 1.00:1.05, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount
of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from
the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt in amount per dosage form of from 15 to 60 mg, based on the weight of edoxaban free base, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the dosage form, a disintegrant, an organic acid in an amount of from 0.1% to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form and one or more further pharmaceutically acceptable excipients, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of edoxaban free base, to the cellulosic polymer is of from 1.00:0.31 to 1.00:0.70, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, and wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said
edoxaban pharmaceutically acceptable salt, the cellulosic polymer, the disintegrant, the organic acid and the one or more further pharmaceutically acceptable excipients.
In a preferred embodiment, edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt is edoxaban comprised in the orodispersible pharmaceutical dosage form of the invention is edoxaban p-toluenesulfonate monohydrate (also referred to as edoxaban tosylate monohydrate).
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention comprises edoxaban tosylate monohydrate in the form of particles having a D(v,90) less than or equal to 50.0 pm as measured by laser light scattering.
The term “edoxaban tosylate monohydrate particles having a D(v, x),” as used herein is defined as meaning that X% of the volume of the edoxaban tosylate monohydrate particles have a diameter equal to or less than a specified diameter. For example, the term “edoxaban tosylate monohydrate particles having a D(v, 90) less than or equal to 50.0 pm” means that 90% of the volume of particles of edoxaban tosylate monohydrate have a diameter less than or equal to 50.0 pm. The particle size distributions (PSD) of edoxaban tosylate monohydrate particles referred herein refer to particle size distributions determined using techniques available in the art, such as laser light scattering technique (e.g. by using a Malvern apparatus). Alternatively, the person skilled in the art may use other equivalent apparatus for measuring particle size distribution (PSD) of edoxaban tosylate monohydrate particles.
Active pharmaceutical ingredients (API) with D(v,90) values of less than or equal to 50.0 pm generally confer to said API poor flowability. In addition, the lower D(v,90) value, the higher difficulty for handling it at the industrial scale,
especially in terms of easiness of manipulation and health & safety for workers. Another drawback from API’s with low D(v,90) values is the undesired effect of segregation of the active ingredient with respect to other pharmaceutically acceptable excipients of the product along the manufacturing process, as well as low values of content of uniformity of the finished medicinal products. Furthermore, API’s with low D(v,90) values may suffer from an increased sensitivity to oxidation due to an increased surface area.
However, in a more preferred embodiment of the invention, the inventors have also surprisingly found that orodispersible dosage forms according to the invention, obtained by direct compression, comprising edoxaban tosylate monohydrate in the form of particles having a D(v,90) less than or equal to 50.0 pm as measured by laser light scattering, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, have excellent flowability and content uniformity, while being easy to manipulate at industrial scale (i.e. thus improving safety for workers). Furthermore, there were not observed segregation problems at an industrial scale.
In a preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an orodispersible tablet.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 3.5% to 12.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 4.00% to 11.50% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a binder in an amount of from 4.5% to 10.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p- toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p- toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, and one or more further pharmaceutically acceptable excipients,
wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p- toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 15.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, an organic acid in an amount of 4.0% w/w relative to the total weight of the orodispersible tablet, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, wherein the organic acid is citric acid or anhydrous citric acid or tartaric acid, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, the organic acid, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 3.5% to 12.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, an organic acid in an amount of 4.0% w/w relative to the total weight of the orodispersible tablet, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group
consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, wherein the organic acid is citric acid or anhydrous citric acid or tartaric acid, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, the organic acid, and the one or more further pharmaceutically acceptable excipients.
In a more preferred embodiment, the orodispersible pharmaceutical dosage form of the invention is an an orodispersible tablet comprising edoxaban p- toluenesulfonate monohydrate, a cellulosic polymer in an amount of from 4.5% to 10.0% w/w relative to the total weight of the orodispersible tablet, a disintegrant, an organic acid in an amount of 4.0% w/w relative to the total weight of the orodispersible tablet, and one or more further pharmaceutically acceptable excipients, wherein the cellulosic polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, wherein the organic acid is citric acid or anhydrous citric acid or tartaric acid, and wherein said orodispersible tablet is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban p-toluenesulfonate monohydrate, the cellulosic polymer, the disintegrant, the organic acid, and the one or more further pharmaceutically acceptable excipients.
As it is mentioned above, a second aspect of the invention relates to a direct compression process for the preparation of the orodispersible dosage form of the first aspect of the invention, which comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients;
(u) blending the mixture of step (i); (in) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form.
In an embodiment, the process for the preparation of the orodispersible pharmaceutical dosage form of the invention comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with a binder, a disintegrant, and one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form.
In an embodiment, the process for the preparation of the orodispersible pharmaceutical dosage form of the invention provides an orodispersible tablet, wherein the process comprises the steps of: (i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with a binder, a disintegrant, and one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending the mixture of step (iii); (v) compressing the dry powdered mixture of step (iv) to form an orodispersible tablet.
In a particular embodiment, the process for the preparation of the orodispersible pharmaceutical dosage form of the invention provides an orodispersible tablet, wherein the process comprises the steps of: (i) mixing edoxaban p- toluenesulfonate monohydrate with a binder, a disintegrant, and one or more further pharmaceutically acceptable excipients; (ii) blending the mixture of step (i); (iii) adding one or more lubricants to the mixture of step (ii); (iv) blending
the mixture of step (in) ; (v) compressing the dry powdered mixture of step (iv) to form an orodispersible tablet.
All the embodiments disclosed above for the orodispersible pharmaceutical dosage form of the invention apply also for the preparation process.
Throughout the description and claims the word "comprise" and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word “comprise” encompasses the case of “consisting of’. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples and drawings are provided by way of illustration, and they are not intended to be limiting of the present invention. Reference signs related to drawings and placed in parentheses in a claim, are solely for attempting to increase the intelligibility of the claim and shall not be construed as limiting the scope of the claim. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.
Examples
Physicochemical characterization of commercially available Lixiana® orally disintegrated tablets in Japan
A sample of 60 mg strength of Lixiana® orally disintegrated tablets commercially available in Japan was purchased and further characterized:
• Description: Uncoated tablet - oval shape with dividing line
• Strength: 60 mg (based on edoxaban free base)
• Average weight: 362.76 mg
• Diameter: 13.406 mm
• Thickness: 4.78 mm
• Hardness: 96.3 N
• Disintegration time: 1 min 45 sec (i.e. 105 seconds)
Disintegration time was obtained by following Test A of the European Pharmacopeia, (edition 10.0, page 323), with water having pH=7, at 37°C and 30 cycles per minute.
Thus, as it can be observed, disintegration time of currently on the market Lixiana® orally disintegrated tablets is far away from the gold-standard in the field - i.e. disintegration time in around 60 seconds or less. In fact, the observed disintegration time almost double the generally accepted maximum value of around 60 seconds.
Example 1: General manufacturing process of orodispersible tablets of the invention
Edoxaban (or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt), a binder and one or more disintegrants are weighed and sieved through a 1 mm mesh and further added to a suitable bin blender (Servo-lift bowl). The following further excipients may be optionally added to the mixture present in the bin blender: a diluent, an organic acid, a sweetener, a glidant, a colorant and a flavouring agent. The mixture is blended between 10 and 25 minutes at 34 rpm. Then, a lubricant is weighed and sieved through a 1 mm mesh and further added to the blended mixture. The obtained mixture is blended 5 minutes at 34 rpm. The obtained dry powdered mixture is compressed in a rotatory press into the desired orodispersible tablets of the invention. A general composition is provided below in Table 1.
Example 2: Qrodispersible tablets compositions according to the invention
Formulations 2 to 5 - as representative examples according to the invention - are shown in Tables 2-3. Said Formulations 2 to 5 were similarly prepared according to the manufacturing process described in Example 1. Qrodispersible tablets of
Formulations 2 to 5 comprised edoxaban p-toluenesulfonate monohydrate (i.e. edoxaban tosylate monohydrate) as active pharmaceutical ingredient. Comparative Formulation 1 (which comprises 2% w/w binder) and Comparative Formulation 6 (which comprises 20% w/w binder) are also shown below in Tables 2-3.
*80.80 mg of edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
*80.80 mg of edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
Example 3. Characterization of orodispersible tablets according to the invention: Disintegration test, hardness, thickness, friability test
Formulations 2 to 5 (according to the invention) and Comparative Formulations 1 and 6, as described in Tables 2-3, were tested for disintegration time following Test A of the European Pharmacopeia (edition 10.0, page 323), water having pH=7, at 37°C and 30 cycles per minute. The results are shown in Table 4.
Formulations 2 to 5 (according to the invention) and Comparative Formulations 1 and 6 were also submitted for friability test in accordance with the guidelines of the European Pharmacopeia, edition 10.0, pp. 336-337. The results are shown in Table 4. Formulations 2 to 5 (according to the invention) and Comparative Formulations 1 and 6 were also characterized by their hardness and thickness.
As shown in Table 4, all orodispersible tablets of Formulations 2 to 5 (according to the invention) complied with the requirement of being orodispersible tablets, in accordance with the definition given by the European Pharmacopeia, edition 10.0, page 939. Furthermore, all disintegrated in around 60 seconds or less - thus being considered as fast/quickly orally disintegrating tablets. Comparative Formulation 6, although it can formally be defined as orodispersible tablet
according to the definition given by the European Pharmacopeia, it needed almost two minutes to completely disintegrate.
Moreover, all orodispersible tablets of Formulations 2 to 5 (according to the invention) complied with the requirement of having a friability of less than 1 % in accordance with guidelines of the European Pharmacopeia.
Example 4. Dissolution profile of orodispersible tablets according to the invention
Dissolution profile of Formulations 2 to 5 (according to the invention), Comparative Formulations 1 and 6, a commercially available film-coated tablet of Lixiana® (60 mg strength) and a Japanese commercially available orally disintegrating tablet Lixiana® (60 mg strength), were measured according to the following dissolution method: (i) USP Apparatus II (paddle); (ii) speed = 50 rpm; (iii) pH=1.2; (iv) volume = 900 mL; (v) temperature = 37 °C; (vi) N=6. The results are shown in Tables 5-6.
Table 5: Dissolution profiles of Lixiana® film-coated tablet (60 mg strength), Lixiana® orally disintegrating tablet (60 mg strength), Comparative Formulation 1 and Formulation 2.
Table 6: Dissolution profiles of Formulations 3, 4, 5 and Comparative Formulation 6.
The dissolution profiles show that orodispersible pharmaceutical dosage forms of the invention (Formulations 2 to 5) rapidly release at least 85% or more of edoxaban within 15 minutes at pH=1.2. When binder is present in low amount (i.e. 2% w/w in Comparative Formulation 1) or too high amount (20% w/w in Comparative Formulation 6), edoxaban is not immediate-released (i.e. less than 85% dissolved within 15 minutes at pH=1.2).
By having such dissolution profile, and thus being sufficiently equivalent to currently marketed Lixiana® conventional tablets, edoxaban orodispersible dosage forms of the invention (Formulations 2 to 5) avoids the risk of being either suprabioequivalent or infrabioequivalent, which may affect the toxicity and/or the efficacy of said orodispersible dosage form.
Example 5: Further orodispersible tablets compositions according to the invention
Further orodispersible tablets of Tables 7-8 were similarly prepared according to the manufacturing process described in Example 1.
*80.80 mg of edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
*80.80 mg of edoxaban tosylate monohydrate correspond to 60.00 mg of edoxaban free base.
Example 6. Characterization of further orodispersible tablets according to the invention: Disintegration test, hardness, thickness, friability test
Formulations 7 to 10 (according to the invention), as described in Tables 7-8, were tested for disintegration time following Test A of the European Pharmacopeia (edition 10.0, page 323), water having pH=7, at 37°C and 30 cycles per minute. The results are shown in Table 9.
Formulations 7 to 10 were also submitted for friability test in accordance with the guidelines of the European Pharmacopeia, edition 10.0, pp. 336-337. The results are shown in Table 9. Formulations 7 to 10 were also characterized by their hardness and thickness.
As shown in Table 9, all orodispersible tablets of Formulations 7 to 10 (according to the invention) complied with the requirement of being orodispersible tablets, in accordance with the definition given by the European Pharmacopeia, edition 10.0, page 939. Furthermore, all disintegrate in around 60 seconds or less - thus being considered as fast/quickly orally disintegrating tablets.
Moreover, all orodispersible tablets of Formulations 7 to 10 (according to the invention) complied with the requirement of having a friability of less than 1 % in accordance with guidelines of the European Pharmacopeia.
Example 7. Dissolution profile of further orodispersible tablets according to the invention
The dissolution profile of Formulations 7 to 10 (according to the invention) was measured according to the following dissolution method: (i) USP Apparatus II (paddle); (ii) speed = 50 rpm; (iii) pH=1.2; (iv) volume = 900 mL; (v) temperature = 37 °C; (vi) N=6. The results are shown in Table 10.
The dissolution profiles show that orodispersible pharmaceutical dosage forms of the invention (Formulations 7 to 10) rapidly release at least 85% or more of edoxaban within 15 minutes at pH=1.2.
By having such dissolution profile, and thus being sufficiently equivalent to currently marketed Lixiana® conventional tablets, edoxaban orodispersible dosage forms of the invention (Formulations 7 to 10) avoids the risk of being either suprabioequivalent or infrabioequivalent, which may affect the toxicity and/or the efficacy of said orodispersible dosage form.
Example 8: Forced degradation studies of formulations of the invention
As representative Formulations according to the invention, Formulations 4 and 10 were subjected to forced degradation studies under different temperature and Relative Humidity (RH) conditions. For comparative purposes, samples of Lixiana® orally disintegrated tablets (ODT) commercially available in Japan and of Lixiana® film-coated tablets (FCT) were also analysed. The forced degradation studies were performed under the following conditions: (a) accelerated conditions at 40 °C/75% RH; (b) thermal degradation at 50 °C. The following impurities were quantified (See Table 11): (i) the amount of 2- (((lS,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4- c]pyridine-2-carboxamido) cyclohexyl)amino)-2-oxoacetic acid (also referred to as “oxoacetic acid impurity”), which is the main degradation impurity of edoxaban by hydrolysis; (ii) the amount of the major unknown impurity; (iii) the amount of total impurities. All values are expressed as % w/w.
As shown in Table 11, representative Formulations according to the invention, prepared by a direct compression process (Formulations 4 and 10) are more stable under forced degradation conditions than commercially available Lixiana® orally disintegrated tablets and Lixiana® film-coated tablets. In particular, the total impurities present in Formulations 4 and 10 are half the amount present in the commercially available products, which are manufactured by wet-granulation.
Example 9: Stability of formulations of the invention
Formulation 11 has an identical quantitative composition than Formulation 10 (see Table 8), except that mint flavour (5% w/w, 21 mg) has been replaced by apricot flavour (5% w/w, 21 mg). Formulation 11 has been identically prepared than Formulation 10.
Formulation 11 was subjected to stability studies, at conditions of 25 °C and 60% Relative Humidity (RH), and it was analyzed at 1, 2 and 3 months. For comparative purposes, samples of Eixiana® film-coated tablets (FCT) were also analysed under the same conditions. The following impurities were quantified (See Table 12): (i) the amount of 2-(((lS,2R,4S)-4-(dimethylcarbamoyl)-2-(5- methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido) cyclo hexyl) amino)-2-oxoacetic acid (also referred to as “oxoacetic acid impurity”), which is the main degradation impurity of edoxaban by hydrolysis; (ii) the amount of the major unknown impurity; (iii) the amount of total impurities. All values are expressed as % w/w.
ND stands for non-detected
As shown in Table 12, Formulation 11 which was prepared by a direct compression process is more stable, under stability studies at 25 °C and 60% RH, than commercially available Lixiana® film-coated tablet. In particular, at 2 and 3-month time analysis, major unknown impurity and total number of impurities was significantly lower in Formulation 11 according to the present invention than commercially available product, which is manufactured by wet-granulation.
Example 10: Manufacturing time comparison between orodispersible formulations manufactured according to the invention and orodispersible formulations of the prior art
As a representative Formulation according to the invention, the manufacturing time needed for obtaining Formulation 10 was compared to the manufacturing time needed for obtaining formulation disclosed in [example 1-2] of EP3549585 Al (See Table 13).
Formulation 10, having a quantitative formulation as described in Example 5 (Table 8), was manufactured according to process described in Example 1 - all the following components were separately weighed and sieved through a 1 mm mesh and further added to a bin blender (Servo-lift bowl): 404.00 g of edoxaban tosylate monohydrate, 645.30 g of D-mannitol, 315.00 g of starch, 210.00 g of crospovidone, 120.00 g of hydroxypropyl methyl cellulose (HPMC), 157.50 g of sodium croscarmellose, 15.40 g of aspartame, 84.00 g of citric acid, 10.50 of colloidal silicone dioxide, 1.80 g of yellow ferric oxide and 150.00 g of mint flavour. Weighing, sieving and adding all components took 60 minutes. The resulting mixture was blended for 15 minutes. Then, 31.50 g of magnesium stearate were weighed and sieved through a 1 mm mesh and further added to the blended mixture. This took 5 minutes. The obtained mixture, containing the magnesium stearate was blended for 5 minutes. The obtained dry powdered mixture was compressed in a rotatory press into the desired orodispersible tablets of the invention. Compression into tablets took 180 minutes.
Formulation disclosed in [example 1-2] of EP3549585 Al was prepared according to the described process therein (i.e. obtaining two different types of granules after two distinct wet- granulation processes). Weighing and adding all
components to the granulator dryer equipment took 60 minutes. Granulation for obtaining the drug-containing granules (i.e. edoxaban-containing granules) took 60 minutes, plus another 60 minutes for drying. Then, weighing and adding all components to the equipment for the second granulation took 60 minutes. Granulation for obtaining the rapidly disintegrating granules took 60 minutes, plus another 60 minutes for drying. The drug-containing granules and rapidly disintegrating granules were mixed and blended for 15 minutes. Then, magnesium stearate was weighed and sieved through a 1 mm mesh and further added to the blended mixture. This took 5 minutes. The obtained mixture, containing the magnesium stearate was blended for 5 minutes. The obtained dry powdered mixture was compressed in a rotatory press into orodispersible tablets, requiring 180 minutes.
Table 13. Manufacturing time comparison between orodispersible formulations manufactured according to the invention and orodispersible formulations of the prior art.
As shown in Table 13, the time employed in the manufacturing of a complete batch of edoxaban orodispersible tablets according to the invention (i.e. by a direct compression process) is less than half as the one required for manufacturing of a complete batch of edoxaban orodispersible tablets according to EP3549585 Al. Thus, direct compression process of the invention provides an improvement in time of manufacturing, leading to a reduction of in economic and energetic manufacturing costs. Citation List
EP3549585
EP3815686
European Pharmacopeia, edition 10.0, page 939
European Pharmacopeia, edition 10.0, page 323 European Pharmacopeia, edition 10.0, pp. 336-337
Guideline for Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.l/Corr., 2010)
Claims
1. An orodispersible pharmaceutical dosage form comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, a binder in an amount of from 3.5% to 15.0% w/w relative to the total weight of the dosage form, a disintegrant, and one or more further pharmaceutically acceptable excipients, wherein said orodispersible pharmaceutical dosage form is obtainable by a direct compression process of a dry powdered mixture comprising edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt, the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients.
2. The orodispersible pharmaceutical dosage form according to claim 1, wherein said orodispersible pharmaceutical dosage form is disintegrated in less than 3 minutes, particularly in less than 2 minutes, and more particularly in less than 1 minute, wherein the disintegration test was performed using a European Pharmacopeia disintegration apparatus A, placing the dosage form in water having pH=7 at 37 °C and 30 cycles per minute.
3. The orodispersible pharmaceutical dosage form according to any of the claims 1-2, wherein the binder is present in an amount of from 3.5% to 12.0% w/w relative to the total weight of the dosage form, preferably of from 4.00% to 11.50% w/w relative to the total weight of the dosage form, more preferably in an amount of 4.5% to 10.0% w/w relative to the total weight of the dosage form.
4. The orodispersible pharmaceutical dosage form according to any of the claims 1-3, wherein the amount of edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt per dosage form is of from 15 to 60 mg, based on the weight of edoxaban free base.
5. The orodispersible pharmaceutical dosage form according to any of the claims 1-4, wherein the weight-to-weight ratio of edoxaban, calculated based on the weight of
89
edoxaban free base, to the binder is of from 1.00:0.21 to 1.00:1.35, preferably of from 1.00:0.24 to 1.00:1.05, and more preferably of from 1.00:0.31 to 1.00:0.70. The orodispersible pharmaceutical dosage form according to any of the claims 1-5, wherein the binder is a cellulosic polymer. The orodispersible pharmaceutical dosage form according to claim 6, wherein the cellulosic polymer is selected from the group consisting of: hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose, ethyl cellulose, sodium carbo xymethyl cellulose, preferably being selected from hydroxypropyl methyl cellulose and hydroxypropyl cellulose. The orodispersible pharmaceutical dosage form according to any of the claims 1-7, wherein said orodispersible pharmaceutical dosage form comprises one or more disintegrants in a total amount of from 5.0% to 20.0% w/w relative to the total weight of the dosage form, preferably of from 7.5% to 17.5% w/w relative to the total weight of the dosage form. The orodispersible pharmaceutical dosage form according to claim 8, wherein said orodispersible pharmaceutical dosage form comprises a first disintegrant and further comprises a second disintegrant which is different from the first disintegrant. The orodispersible pharmaceutical dosage form according to claim 9, wherein the weight-to-weight ratio of the first disintegrant to the second disintegrant is of from 3.00:1.00 to 1.00:1.00, preferably of from 2.50:1.00 to 1.00:1.00, more preferably of from 2.00:1.00 to 1.00:1.00, and even more preferably of from 1.50:1.00 to 1.00:1.00. The orodispersible pharmaceutical dosage form according to any of the claims 1-10, wherein the one or more disintegrants is/are selected from the group consisting of: crospovidone, croscarmellose sodium, carmellose calcium, carmellose, calcium silicate and sodium starch glycolate and mixtures thereof. The orodispersible pharmaceutical dosage form according to any of the claims 1-11, wherein said dosage form further comprises an organic acid in an amount of from 0.1%
90
to 20.0% w/w relative to the total weight of the dosage form, preferably in in an amount of from 0.5% to 15.0% w/w relative to the total weight of the dosage form, more preferably in in an amount of from 0.75% to 10.0% w/w relative to the total weight of the dosage form, and even more preferably in an amount of from 1.0% to 8.0% w/w relative to the total weight of the dosage form. The orodispersible pharmaceutical dosage form according to claim 12, wherein said dosage form comprises an organic acid selected from the group consisting of: adipic acid, aspartic acid, ascorbic acid, alginic acid, benzoic acid, citric acid, anhydrous citric acid, glutamic acid, succinic acid, tartaric acid, sorbic acid, lactic acid, fumaric acid, maleic acid, malonic acid, malic acid, oxalic acid, galactaric acid, gluconic acid, and glucuronic acid, preferably being selected from citric acid, anhydrous citric acid, tartaric acid and fumaric acid. The orodispersible pharmaceutical dosage form according to claim 12, wherein the organic acid is citric acid or anhydrous citric acid or tartaric acid and wherein said organic acid is present in an amount of 4.0% w/w relative to the total weight of the dosage form. The orodispersible pharmaceutical dosage form according to any of the claims 1-13, wherein the percentage-to-percentage ratio of organic acid to one or more disintegrants is of from 1.00:1.875 to 1.00:17.50, preferably of from 1.00:3.125 to 1.00:17.50, and more preferably of from 1.00:4.375 to 1.00:17.50. The orodispersible pharmaceutical dosage form according to any of the claims 1-15, wherein the direct compression process comprises the steps of:
(i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients,
(ii) blending the mixture of step (i),
(iii) adding one or more lubricants to the mixture of step (ii),
(iv) blending the mixture of step (iii),
91
(v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form. The orodispersible pharmaceutical dosage form according to any of claims 1-16, wherein the edoxaban or the pharmaceutically acceptable salt thereof or the hydrate of said edoxaban or the hydrate of said edoxaban pharmaceutically acceptable salt is selected from the group of edoxaban tosylate, edoxaban tosylate monohydrate, edoxaban methanesulfonate and edoxaban benzenesulfonate, preferably being edoxaban tosylate monohydrate. The orodispersible pharmaceutical dosage form according to claim 17, wherein edoxaban tosylate monohydrate is present in the form of particles having a D(v,90) less than or equal to 50.0 pm as measured by laser light scattering. The orodispersible pharmaceutical dosage form according to any of claims 1-18, wherein said orodispersible pharmaceutical dosage form is an orodispersible tablet. The orodispersible pharmaceutical dosage form according to any of claims 1-19 for use in the treatment of: a) prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age > 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA); and/or b) treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults; and/or c) prevention of venous thromboembolism (VTE) in patients undergoing any of the following orthopedic surgeries for the lower limbs: total knee replacement, total hip replacement, and hip fracture surgery. A process for the preparation of the orodispersible pharmaceutical dosage form as defined according to any of claims 1-19, which comprises the steps of:
(i) mixing edoxaban or a pharmaceutically acceptable salt thereof or a hydrate of said edoxaban or a hydrate of said edoxaban pharmaceutically acceptable salt with the binder, the disintegrant, and the one or more further pharmaceutically acceptable excipients,
(ii) blending the mixture of step (i),
92
(iii) adding one or more lubricants to the mixture of step (ii),
(iv) blending the mixture of step (iii),
(v) compressing the dry powdered mixture of step (iv) to form an orodispersible pharmaceutical dosage form.
93
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3234371A CA3234371A1 (en) | 2021-11-22 | 2022-11-21 | An orodispersible pharmaceutical dosage form of edoxaban |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121053646 | 2021-11-22 | ||
IN202121053646 | 2021-11-22 | ||
EP22152174.3A EP4183390A1 (en) | 2021-11-22 | 2022-01-19 | An orodispersible pharmaceutical dosage form of edoxaban |
EP22152174.3 | 2022-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023089575A1 true WO2023089575A1 (en) | 2023-05-25 |
Family
ID=84488544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/061193 WO2023089575A1 (en) | 2021-11-22 | 2022-11-21 | An orodispersible pharmaceutical dosage form of edoxaban |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3234371A1 (en) |
WO (1) | WO2023089575A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013026553A1 (en) * | 2011-08-22 | 2013-02-28 | Ratiopharm Gmbh | Composition comprising edoxaban |
EP3549585A1 (en) | 2016-12-01 | 2019-10-09 | Daiichi Sankyo Company, Limited | Orally disintegrating tablet including diamine derivative |
EP3744320A1 (en) * | 2019-05-29 | 2020-12-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising edoxaban |
CN112618498A (en) * | 2019-09-24 | 2021-04-09 | 北京万全德众医药生物技术有限公司 | Edoxaban tosylate orally disintegrating tablet and preparation method thereof |
EP3815686A1 (en) | 2018-06-27 | 2021-05-05 | Daiichi Sankyo Company, Limited | Granular preparation containing diamine derivative |
-
2022
- 2022-11-21 WO PCT/IB2022/061193 patent/WO2023089575A1/en active Application Filing
- 2022-11-21 CA CA3234371A patent/CA3234371A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013026553A1 (en) * | 2011-08-22 | 2013-02-28 | Ratiopharm Gmbh | Composition comprising edoxaban |
EP3549585A1 (en) | 2016-12-01 | 2019-10-09 | Daiichi Sankyo Company, Limited | Orally disintegrating tablet including diamine derivative |
EP3815686A1 (en) | 2018-06-27 | 2021-05-05 | Daiichi Sankyo Company, Limited | Granular preparation containing diamine derivative |
EP3744320A1 (en) * | 2019-05-29 | 2020-12-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising edoxaban |
CN112618498A (en) * | 2019-09-24 | 2021-04-09 | 北京万全德众医药生物技术有限公司 | Edoxaban tosylate orally disintegrating tablet and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
"European Pharmacopeia", pages: 336 - 337 |
MARKL DANIEL ET AL: "A Review of Disintegration Mechanisms and Measurement Techniques", PHARMACEUTICAL RESEARCH, SPRINGER US, NEW YORK, vol. 34, no. 5, 1 March 2017 (2017-03-01), pages 890 - 917, XP036788609, ISSN: 0724-8741, [retrieved on 20170301], DOI: 10.1007/S11095-017-2129-Z * |
Also Published As
Publication number | Publication date |
---|---|
CA3234371A1 (en) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI702953B (en) | Pharmaceutical compositions and tablets comprising azd9291, and use of the same | |
JP5537943B2 (en) | Fast disintegrating solid preparation | |
KR101360526B1 (en) | Pharmaceutical forms with improved pharmacokinetic properties | |
JP5296456B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
JP4920798B2 (en) | Intraoral quick disintegrating tablet containing two or more kinds of particles | |
WO2013161823A1 (en) | Orally disintegrating tablet and method for producing same | |
Amrutkar et al. | Design and evaluation of taste masked chewable dispersible tablet of lamotrigine by melt granulation | |
JP2008536922A (en) | Olanzapine pharmaceutical orally disintegrating tablets | |
JP2008094837A (en) | Masking for bitter taste | |
CA2938909A1 (en) | Orally disintegrating tablet of nabilone comprising mannitol-based granules | |
JP2017141299A (en) | Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet | |
Alburyhi et al. | Formulation, Development and Evaluation of Famotidine Orodispersible Tablets | |
EP2255810A1 (en) | Pharmaceutical forms comprising vardenafil and having a controlled bioavailability | |
EP2243468A1 (en) | Orally Disintegrating Dimebolin Compositions | |
JP5978335B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
EP4183390A1 (en) | An orodispersible pharmaceutical dosage form of edoxaban | |
WO2023089575A1 (en) | An orodispersible pharmaceutical dosage form of edoxaban | |
JP7148319B2 (en) | Orally disintegrating tablet containing prasugrel | |
WO2011049122A1 (en) | Pravastatin sodium tablet rapidly disintegrating in oral cavity and method for producing same | |
JP6328138B2 (en) | Of N- [5- [2- (3,5-dimethoxyphenyl) ethyl] -2H-pyrazol-3-yl] -4-[(3R, 5S) -3,5-dimethylpiperazin-1-yl] benzamide Pharmaceutical formulation | |
JP6151413B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
BR112019028278A2 (en) | pharmaceutical compositions | |
WO2023194885A1 (en) | An orodispersible tablet of rivaroxaban | |
JP5714652B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
WO2023128902A1 (en) | Pharmaceutical compositions comprising bosentan and relevant excipients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22822654 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3234371 Country of ref document: CA |